

Drug quantification in single 3D organoids reveals correlation to reported in vivo brain uptake and demonstrates translational relevance for prediction of blood-brain barrier permeability

Cindy Bay

Heidelberg University <https://orcid.org/0000-0003-3898-3148>

Meike Kästing

Heidelberg University

Jiayi Chu

Heidelberg University

Eric Mühlberg

Heidelberg University <https://orcid.org/0000-0002-0294-3120>

Camilo Scherkl

Heidelberg University <https://orcid.org/0009-0008-8569-1694>

Philipp Uhl

Heidelberg University <https://orcid.org/0000-0002-8616-5599>

Julia Carolin Stingl

Heidelberg University <https://orcid.org/0000-0002-1566-8156>

Jürgen Burhenne

Heidelberg University <https://orcid.org/0000-0002-2190-1698>

Gzona Bajraktari-Sylejmani

Heidelberg University <https://orcid.org/0000-0001-7870-1542>

Max Sauter

Heidelberg University <https://orcid.org/0000-0003-4977-1925>

Johanna Weiss

Johanna.Weiss@med.uni-heidelberg.de

Heidelberg University <https://orcid.org/0000-0002-2034-923X>

Research Article

Keywords: 3D blood-brain barrier organoids, blood-brain barrier, paracellular marker, permeability, liquid chromatography tandem mass spectrometry, drug screening, New Approach Methodologies

Posted Date: October 21st, 2026

DOI: <https://doi.org/10.21203/rs.3.rs-11433171/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.
[Read Full License](#)

Additional Declarations: The authors declare no competing interests.

Drug quantification in single 3D organoids reveals correlation to reported *in vivo* brain uptake and demonstrates translational relevance for prediction of blood-brain barrier permeability

Cindy Bay¹, Meike Kästing¹, Jiayi Chu¹, Eric Mühlberg^{2,3}, Camilo Scherkl¹, Philipp Uhl^{3,4}, Julia Carolin Stingl¹, Jürgen Burhenne¹, Gzona Bajraktari-Sylejmani¹, Max Sauter^{1,†}, Johanna Weiss^{1,†,*}

1) Heidelberg University, Medical Faculty Heidelberg / Heidelberg University Hospital, Internal Medicine IX - Department of Clinical Pharmacology and Pharmacoepidemiology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

2) Heidelberg University, Medical Faculty Heidelberg / University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany

3) Heidelberg University, Institute for Pharmacy and Molecular Biotechnology, Department of Pharmaceutical Technology and Biopharmacy, Im Neuenheimer Feld 329, 69120 Heidelberg, Germany

4) Aalen University, Faculty of Chemistry, Beethovenstraße 1, 73430 Aalen, Germany

† These authors contributed equally to this work

* Corresponding author:

Prof. Dr. Johanna Weiss

Heidelberg University, Medical Faculty Heidelberg, Heidelberg University Hospital, Internal Medicine IX – Department of Clinical Pharmacology and Pharmacoepidemiology, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany

Tel: +49-6221/5639402

Fax: +49-6221/564642

Email address: johanna.weiss@med.uni-heidelberg.de

Abstract:

Evaluation of blood-brain barrier (BBB) permeability is a crucial step in drug research and development, particularly for the pharmacotherapy of targets in the central nervous system. Current preclinical permeability predictions are hindered by limited transferability or BBB model inaccessibility for analysis. In order to generate relevant pharmacological data, it is necessary to establish qualified physiological, translational, and quantitative systems with validated methods.


3D BBB organoids composed of human cerebral microvascular endothelial cells (hCMEC/D3), and primary pericytes and astrocytes were generated. The BBB barrier function was evaluated using the paracellular marker D-Tyr(Me)Orn. Confocal laser scanning microscopy was used to determine the architecture of the cell arrangements, crucial BBB hallmarks and the apoptosis rate (cleaved caspase 3). An experimental setup was established to evaluate drug uptake into the organoids using ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). The concentration- and time-dependent intraorganoidal drug uptake was determined for 13 drugs, and used to calculate the ratio of intra- and extraorganoidal concentrations. These organoid uptake ratios were subsequently correlated with reported *in vivo* brain-to-plasma ratios. Additionally, the performance of four *in silico* BBB permeability prediction tools was assessed with the *in vivo* data.

Optimal analysis time point was identified as day 3 post self-assembly based on organoid architecture, endothelial coverage and apoptosis rate. Modular barrier properties were shown by a reduction of intraorganoidal D-Tyr(Me)Orn after cell connection were compromised, and potential wash out cross-validated by fluorescent Cy5 in the wash solution. Deming regression demonstrated a correlation with pseudo R^2 of 0.64 between the organoid uptake ratios and reported mammalian *in vivo* brain-to-plasma ratios. In contrast, the *in silico* tools evaluated displayed no correlations with these *in vivo* data.

We established and validated a simple and rapid experimental setup for the UPLC-MS/MS drug quantification into single 3D BBB organoids. We demonstrated that the 3D BBB organoids have translational relevance with regard to human and mammalian *in vivo* BBB permeability. This system therefore qualifies as New Approach Methodology (NAM) and can be used for approximate evaluation of *in vivo* brain uptake, while outperforming state of the art *in silico* models.

Keywords: 3D blood-brain barrier organoids; blood-brain barrier; paracellular marker; permeability; liquid chromatography tandem mass spectrometry; drug screening, New Approach Methodologies.

Graphical abstract:



Background

The translational relevant evaluation of blood-brain barrier (BBB) permeability in preclinical models is essential for the development of drug candidates, especially for central nervous system (CNS) pathologies. Because the BBB is highly restrictive, the majority of drugs reach minimal exposure in the CNS^{1,2}. Currently, many CNS pathologies are still not accessible to efficacious therapeutic options. Although the BBB can be impaired in pathological states such as brain tumors, it can still prevent an effective drug treatment of CNS malignancies. Brain tumors are a type of CNS diseases with a particularly poor prognosis, and they can result in a less restrictive blood-tumor barrier (BTB). But effective pharmacotherapy requires drug access to all cancer cells to prevent relapse. This includes infiltrating cells that are farther away from the BTB and metastases that can often localize behind an intact BBB^{3,4}.

The scarcity of human BBB permeability data is mainly caused by limited accessibility and invasive sampling as a major hurdle for clinical monitoring of CNS drug exposure. While animal data is abundant, it suffers from the usual limitations of species differences in particular with regard to receptor and transporter mediated uptake and efflux, resulting in remaining uncertainty for clinical efficacy or safety⁵⁻¹². In addition, limiting the use of animals for preclinical research is a main goal for ethically responsible research, with extensive general regulatory support¹³⁻¹⁵.

Studies in animals have demonstrated limited predictability of human drug safety and efficacy reflected by the high attrition rate of clinical candidates evaluated with animal toxicological studies^{15,16}. In context of BBB permeability, this is especially evident for P-glycoprotein (P-gp) substrates in rodents⁵⁻¹⁰. Many alternative *in vitro* models have historically relied on cell lines and suffer from similar or more pronounced drawbacks of animal experiments in regard to translational relevance^{17,18}. The huge variety of current *in vitro* BBB models represents a tradeoff between the physiological replication of the complex BBB architecture and function and accessibility for analysis. Nevertheless, *in vitro* models have decisive advantages. They offer a much higher throughput with lower resource demand and, importantly, help to reduce the number of laboratory animals (e.g. 3R principle: reduce, replace, refine¹⁴). At the same time, they can be composed entirely of human cells, thus circumventing species differences. Translationally relevant models are therefore urgently required to accelerate drug

development. With the rise of New Approach Methodologies (NAMs) and their recent acceptance in toxicological testing by the FDA¹⁵, drug development is undergoing a silent revolution. NAM include human primary cells, induced pluripotent stem cell (iPS)-derived cells, computational models, AI-predictions, organ-on-a-chip, and organoids. Moving to human-centric testing promises more relevant insights into human physiological and biological response, and mechanisms of toxicity. A key prerequisite of NAM use in regulatory preclinical testing is their qualification consisting of the demonstration of their reliability, reproducibility, and the fit-for-purpose. Especially in the context of the BBB, organoid models, like other NAMs, are essential for achieving the interaction between astrocytes, pericytes and endothelial cells that facilitates the most restrictive barrier in human physiology.

We aimed to establish a NAM model for BBB permeability and qualify its translational relevance. We selected a simple self-assembling 3D organoid^{19,20} that allows direct interaction of endothelial cells, astrocytes, and pericytes as the key BBB architecture. While brain capillary endothelial cells (BCEC), are the main BBB component, the additional cell types have been shown to contribute significantly to BBB establishment and maintenance *in vivo*²¹⁻³² and to the BBB phenotype of endothelial cells *in vitro*³³⁻⁴⁷. These organoids are easy to reproduce and comparatively cost-efficient. They are fully human and the cell types used (hCMEC/D3 and primary astrocytes and primary pericytes) are readily available. In the 3D BBB organoid astrocytes and pericytes can interact freely and are surrounded by a continuous layer of the BCEC hCMEC/D3 cells²⁰. Endothelial cells of these organoids express crucial BBB hallmarks, such as Zonula occludens 1 (ZO-1), claudin-5, low density lipoprotein receptor-related protein 1 (LRP-1), the transferrin receptor, and P-gp^{20,48}. P-gp-mediated transport was demonstrated to be functionally active^{20,49}, as was the transcytosis mediated by the transferrin and LRP-1 receptors^{20,48}. This model has been used for targeting construct assessment, antibody uptake^{20,48} and toxicology screening⁴⁹. As an initial proof-of-concept, the penetration of two drugs was qualitatively evaluated with matrix-assisted laser desorption/ionization (MALDI) imaging^{19,20}. The presence of a functional barrier was previously mainly demonstrated by increased high molecular marker uptake after tight junction (TJ) opening, like dextran uptake after VEGF treatment²⁰, which is a limited discriminative marker for the maximal restrictive BBB based on its large size.

113 Our ambition was the development of a translationally qualified permeability methodology based on the
114 optimization of these NAM organoid culture establishing a high-throughput analysis of drug uptake on
115 single organoid level via highly sensitive ultra-performance liquid chromatography tandem mass
116 spectrometry (UPLC-MS/MS) measurements. For this purpose, we investigated the uptake of the
117 validated highly discriminative paracellular marker D-Tyr(Me)Orn⁵⁰ and 13 drug (candidates) with
118 known brain concentrations *in vivo* in the context of emerging therapies for brain tumor treatment. Our
119 aim was to establish a NAM for BBB permeability. Therefore, our main objective was to evaluate the
120 *in-vitro-in-vivo* correlation and thereby the translational relevance of the organoid model for the
121 prediction of human BBB permeability.

Methods

Materials

hCMEC/D3 were purchased from Cellutions Biosystems Inc. (Burlington, Canada), normal hippocampal primary astrocytes from Innoprot (Bizkaia, Spain) and primary human vascular pericytes and Pericyte Medium (PM) from ScienCell Research Laboratories (Carlsbad, CA, USA). Endothelial Growth Medium 2 SingleQuots™ (EGM-2™) and Astrocyte Growth Medium (AGM™) were provided by Lonza (Basle, Switzerland). Roswell Park Memorial Institute (RPMI) 1640 medium was obtained from PAN Biotech (Aidenbach, Germany). Cell+ flasks with vented caps and standard cell culture flasks were purchased from Sarstedt (Nuremberg, Germany).

Akura™ 96 spheroid microplates were obtained from Insphero (Schlieren, Switzerland). Antibodies were obtained as followed: mouse anti-human ZO-1 (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), mouse anti-human P-gp (BD Biosciences, Heidelberg, Germany), mouse anti-human CD31 ab9498 (Dako, Santa Clara, CA, USA), rabbit anti-active caspase 3 (R&D Systems, Minneapolis, MN, USA); goat anti-mouse Alexa-Fluor® 488 secondary antibody (Abcam, Cambridge, UK) goat anti-rabbit Alexa-Fluor® 488 secondary antibody, anti-mouse Alexa-Fluor® 647 secondary antibody (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). CellTracker™ Deep Red was also purchased from Invitrogen (Thermo Fisher Scientific, Waltham, MA, USA). Penicillin-streptomycin solution, Dulbecco's phosphate-buffered saline (PBS), Hanks Balanced Salt Solution (HBSS), trypsin-ethylenediamine tetraacetic acid (EDTA) solution (0.5 g porcine trypsin and 0.2 g EDTA/L), fetal bovine serum (FBS), 1 M HEPES buffer, lactate dehydrogenase (LDH) assay, dimethyl sulfoxide (DMSO), Fluoroshield™ with DAPI, adenosine, Triton X-100, human serum (male AB) and collagenase IV were purchased from Sigma-Aldrich (Taufkirchen, Germany). Ethylene glycol tetraacetic acid (EGTA) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). HumanKine® recombinant human vascular endothelial growth factor (VEGF)₁₆₅ protein was purchased from Proteintech (Planegg-Martinsried, Germany). Tert-butyl methyl ether (TBME) and the ammonia solution (NH₄OH, aqueous 28%) were provided by Merck (Darmstadt, Germany). CellTiter-Glo® 3D Cell Viability Assay was obtained from Promega (Madison, USA). Human albumin 20% was obtained from CSL Behring (Marburg, Germany). Bovine albumin fraction V (BSA) and Tween®-20

were purchased from AppliChem (Darmstadt, Germany). The acetonitrile (ACN), and formic acid (FA) were from Biosolve (Valkenswaard, The Netherlands) all at highest analytical purity. Ultra-purified water was produced with the Arium[®] mini water system (Sartorius, Göttingen, Germany). Hydrochloric acid (HCl) and sodium hydroxide (NaOH) and were provided by Honeywell (Seelze, Germany).

Repotrectinib, futibatinib, lorlatinib, and larotrectinib were purchased from MedKoo Biosciences (Durham, USA); [²H₆]-futibatinib, [²H₃, ¹³C₁]-lorlatinib, [²H₄]-larotrectinib, temsirolimus and [¹³C₃, ²H₇]-temsirolimus were purchased from AlsaChim Shimadzu, (Illkirch-Graffenstaden, France); ulixertinib and [²H₆]-ulixertinib were obtained from BioMedValley, Asymchem Life Science, (Tianjin, China); olaparib and [²H₄]-olaparib were purchased from Biozol GmbH (Hamburg, Germany). Selinexor was obtained from Selleckchem (Cologne, Germany), hypericin from Dr. Willmar Schwabe Pharmaceuticals (Karlsruhe, Germany), fluoxetine from Sulpelco Sigma-Aldrich (Taufkirchen, Germany), [²H₆]-fluoxetine from Cerilliant (Round Rock, TX, USA), octreotide from BACHEM (Bubendorf, Switzerland), [¹³C₆]-octreotide from TRC (Vaughan, ON, Canada), paroxetine from EDQM (Strasbourg, France), diazepam from Serva Feinbiochemica (Heidelberg, Germany), senicapoc from MedChemExpress (Monmouth Junction, NJ, USA) and selitrectinib from Hycultec GmbH (Beutelsbach, Germany).

The synthesis of D-Tyr(Me)Orn and the stable isotopically labeled D-Tyr([²H₃]Me)Orn has been reported previously⁵⁰.

Stock solutions and dilutions

The drugs were dissolved in PBS with a minimal concentration of DMSO when necessary (generally < 0.1% except for highest concentration of selitrectinib with 1.31% and olaparib with 0.15%). D-Tyr(Me)Orn was stored in a 40 mM stock solution in PBS. All working solutions were freshly prepared after thawing on ice as described in the respective experimental section. The EGTA solution (5 mM) was prepared by diluting the 10 mM EGTA powder in PBS and adjusting the PH to ~ 8 and subsequent dilution in cell culture medium. The 1:10 dilution of trypsin was performed in PBS. Lyophilized VEGF was dissolved in PBS with 1% human serum albumin to a concentration of 100 µg/mL. Adenosine was dissolved in PBS to a concentration of 40 mM. Collagenase IV was dissolved in PBS to a concentration of 15 mg/mL and frozen in aliquots. For organoid lysis, the collagenase IV was thawed and diluted

further to 3 mg/mL in PBS. All stock solutions were prepared in their respective solvents and stored in appropriate aliquots at -20 °C.

Cell culture and *in vitro* experiments

hCMEC/D3 cells, primary human astrocytes and pericytes were cultured separately in Cell+ culture flasks in a CO₂ incubator at 37 °C and with 5% CO₂. The hCMEC/D3 cells were kept in EGM-2 medium, the astrocytes in AGM medium and the pericytes in PM medium, each medium mixed with all respective supplements. The cells were washed with HHBSS and detached with trypsin solution for the minimum required time. Detachment was stopped by adding RPMI medium supplemented with a penicillin-streptomycin solution (100 U/mL and 100 µg/mL) and 10% FBS. hCMEC/D3 were used until and including passage 35, astrocytes until passage 5 and pericytes until passage 10 (as previously reported¹⁹).

Organoid generation

Organoids were generated as described by¹⁹, with the following adaption: 1,500 of each cell type, counted using the MACSQuant[®] Analyzer (Miltenyi Biotec), were transferred to one well of an Akura[™] spheroid microplate for self-assembly (day 0). To reduce smaller secondary organoids, the medium was changed after 24 h (day 1). Afterwards, gentle rotation on the rotation shaker in the CO₂ incubator was applied for the remaining culture duration to induce shear stress through flow. Unless otherwise stated, all experiments were performed on day 3 after assembly. As previously published, the organoids were cultured in organoid medium (EGM-2 without VEGF and FBS, supplemented with 2% human serum). This resulted in one organoid per well of the spheroid plate.

Staining and immunofluorescence

For CellTracker[™] staining, the described procedure²⁰ was adapted as follows: cells were stained in the cell culture flask with 5 µM CellTracker[™] solution in HHBSS before detachment. After a 15-min incubation at 37 °C, the cells were washed twice with warm HHBSS, detached with trypsin solution and centrifuged. The cells were then gently resuspended in the organoid medium and used for organoid generation. After the respective culture time, the organoids were fixed for 1 h with a 4% formaldehyde solution.

For separate or combined immunostaining, the Stemcell[™] Technologies protocol „performing immunocytochemical staining of epithelial organoids“ was used for orientation. All incubation steps

were performed at room temperature on an orbital shaker and all washing steps lasted 5 min. The organoids were pooled in low-adherence reaction tubes. After formaldehyde fixation, the organoids were incubated for 30 min in a 0.3 M glycine solution and washed three times with an immunofluorescence-buffer (IF-buffer, 0.1% BSA (w/v), 0.2% Triton-X-100 (v/v), 0.05% Tween 20 (v/v) in PBS). The organoids were either directly permeabilized and blocked (5% BSA (w/v), 1% Triton-X-100 (v/v) in PBS) overnight or stored in PBS at 4 °C. After permeabilization staining with the respective primary antibody was performed overnight. The antibodies (CD31, ZO-1, P-gp, Cas3) were diluted 1:100 in IF buffer. After 3 washing steps with the IF buffer, the organoids were incubated overnight with the respective secondary antibody, diluted 1:1000 in buffer (IF-buffer with 10% BSA (w/v)). The organoids were then washed with salt-free water, followed by PBS.

To improve imaging quality, all samples were cleared with methanol: after 1 h incubation at room temperature with PBS/methanol (1/1, v/v) a second incubation with 100% methanol was performed. Both steps were carried out at room temperature under gentle agitation. As much methanol as possible was removed and 2 drops of Fluoroshield™ with DAPI were added. Microscopic slides were prepared with thick adhesive tape on both sides. The organoids were slowly transferred to the middle of the slide with a pipette. A cover slip was placed on top of the adhesive film to prevent smashing the organoids. If necessary, more Fluoroshield™ was added to encompass the entire area under the cover slip. The cover slips were left at room temperature overnight to dry for imaging the following day.

Microscopy and image processing

Light sheet microscopy was performed using a Leica DMI1 microscope. Confocal laser scanning microscopy (CLSM) was performed at the Nikon Imaging Center of Heidelberg University using a Nikon AX eclipse Ti2 with a silicon oil immersion objective (Nikon PLAN APO 40 ×/1,25 SIL λS) and the NIS Elements software (Nikon Instruments, Inc.).

Image processing was performed using ImageJ2 (as part of Fiji)⁵¹. Z-stacks were imaged and used for maximum intensity projections and orthogonal views. The organoid circumference was determined using the measurement function for the region of interest (ROI). Brightness and contrast adjustments were always applied linearly over the entire image. These parameters were set qualitatively for each

image. If the settings were identical for quantitative comparison, this is indicated under the respective figure.

For the quantitative analysis of cleaved caspase 3 (Cas3) staining, the proportion of the positive region in the ROI (the entire organoid area in the respective z-slice) was determined. Therefore, raw unprocessed 16-bit images were used. The respective fluorescence channel was separated and the positive proportion was determined using the threshold function in ImageJ. At equal intervals 3 z-slices within the first 50 μm of each organoid were analyzed. The results for each staining, imaging and organoid generation were normalized to the respective mean of the day 3 sample.

D-Tyr(Me)Orn and drug uptake in organoids

For all uptake experiments, organoids were generated as described and cultured until day 3. For modulation of paracellular tightness, the endothelial cell layer was compromised with multiple orthogonal approaches by pre-incubation with either 20 or 200 ng/mL of VEGF, 1 and 10 μM of adenosine in organoid medium, 5 mM EGTA, 0.5 mM EDTA solution, or a 1:10 dilution of trypsin in PBS. Incubation times are indicated on the respective graph. The control group was incubated with fresh organoid medium. After pre-incubation, the solutions were removed and 300 μM D-Tyr(Me)Orn in organoid medium supplemented with 7% human serum albumin was added. The samples were then incubated for 1 h at 37 °C under gentle agitation in the CO₂ incubator.

For drug uptakes, the respective drug was diluted in organoid medium supplemented with 7% human serum albumin to the concentrations indicated in Table 1. The incubation was performed for the time described in the graphs at 37 °C under gentle agitation in the CO₂ incubator. Time-dependent uptake was performed to determine the steady-state concentration.

After the respective incubations, the spheroid plates were placed on ice and washed five times with ice-cold PBS supplemented with 2% BSA, followed by one final wash with pure PBS. As much of the remaining liquid in the wells as possible was removed. The presence of organoids was verified under the light microscope. The organoids were lysed enzymatically by adding 20 μL of collagenase IV (3 mg/mL in PBS) to each well and incubating under agitation for 1 h at 37 °C. Then, 20 μL of trypsin solution was added, and the plate was incubated further at 37 °C for 1 h. Lysis was finalized by adding

10 µL of a 28% aqueous ammonia solution. Complete and reproducible lysis was verified under a light microscope.

For the fluorescent marker substances hypericin (2 µM) and Cy5 (300 µM), incubation was performed accordingly. After incubation, the organoids were washed and fixed for 1 h with 4% formaldehyde. The organoids were fixed on microscopic slide as described for immunofluorescence analysis with Fluoroshield™ with DAPI. Additionally, the fluorescence in the wash solutions was determined using a SpectraMax® with and without pre-incubation with 200 ng/mL VEGF for 4 h (Cy5: 630/670 nm; hypericin: 590/650 nm).

Viability and cytotoxicity assay

Organoids (n ≥ 3) were incubated with the respective highest drug concentration for the longest used incubation time, thereby also including the evaluation of the highest DMSO concentration used. Subsequently, viability was determined using the CellTiter-Glo® 3D Cell Viability Assay as recommended by the manufacturer. The sample and reaction solution volumes were set to 50 µL. The negative control was treated with 1% Triton-X-100 and the positive control was left untreated. Background controls were performed for the medium and drug solutions. Luminescence was measured using a SpectraMax® plate reader.

Cytotoxicity was measured by adding 100 µL of the incubation supernatant to 100 µL of freshly prepared LDH assay reaction solution. Absorption was determined using a SpectraMax® plate reader at 490 nm. The positive and negative controls were reversed by definition. Normalized viability and cytotoxicity were then calculated using the formula:

$$viability/cytotoxicity [\%] = \frac{sample - negativ\ control}{positive\ control - negative\ control} \times 100$$

Sample preparations and analytical method for D-Tyr(Me)Orn UPLC-MS/MS quantification

D-Tyr(Me)Orn was quantified as previously reported⁵⁰. For organoid samples, 25 µL of the internal standard (IS) D-Tyr([²H₃]Me)Orn were added to approximately 50 µL of lysed organoid. After shaking the solution on a plate shaker and pipetting it up and down, 35 µL were transferred to a new 96-well microtiter plate. Calibration and QC solutions were prepared in the organoid matrix: 1,500 cells of each cell type were incubated as described for organoid lysis with 20 µL of collagenase IV, 20 µL of trypsin

solution and 10 μ L of 28% aqueous ammonia. This solution was manufactured on a larger scale and stored in aliquots at -20 °C. 50 μ L of this matrix were mixed with 25 μ L of the IS solution and 35 μ L were transferred to a new plate. The respective calibration or QC solution was then added. The remaining sample preparation and UPLC-MS/MS were identical to those published previously⁵⁰. In brief, 25 μ L of H₂O/ACN (75/25, v/v) + 0.1% FA were added to the study samples to compensate for the volume of the calibration or QC solution. Then, protein precipitation was performed with 100 μ L of ACN + 0.1% FA. After shaking, the plate was centrifuged and transferred into the sample manager of the UPLC-MS/MS system. Quantification was performed on a triple quadrupole system TQ-XS (Waters, Milford, MA, USA) in positive ion mode with collision-induced dissociation using argon gas (CID) after z-electrospray ionization (ESI) and multiple reaction monitoring (MRM).

Drug quantification

All UPLC-MS/MS assays in this study were performed on triple quadrupole tandem mass spectrometers with z-ESI, stepwave optimization and CID (Waters Xevo TQ-XS and two separate TQ-S systems: TQ-S1 was coupled with a Waters Binary Solvent Manager Acquity Classic UPLC®, and TQ-S2 was coupled with UPLC I-class® and Waters Binary Solvent Manager FTN®). The systems were coupled with a Waters Acquity Column and Binary Solvent Manager. The respective analytical parameters of the MS and the chromatography for all drugs tested (Table 1), are listed in Supplement Table S1. The analytical parameters for all drugs were determined by the automatic IntelliStart software after direct infusion into the MS system.

Organoid matrix was used as a matrix for calibrator and QC samples, as described for D-Tyr(Me)Orn quantification. To 50 μ L of the organoid matrix, 25 μ L of the respective IS was added. After thorough mixing, 35 μ L of the solution were transferred. Next, 25 μ L of the respective calibration and QC solutions were added. For the study samples, each lysed organoid was mixed with 25 μ L of the IS, and then 35 μ L were transferred into a fresh plate. Sample preparation was then performed as summarized in Table 2. All sample preparations were performed in 96-well plates, and the transfer steps were carried out with a multichannel pipette. Centrifugation steps were performed for 10 min at 1000 $\times$ g after the protein precipitation. The solvent was evaporated for 15 min at 40 °C under nitrogen. The mass spectrometry and chromatography parameters for olaparib, and ulixertinib have already been published

previously^{52,53}, and the sample preparation and calibration range herein were adapted for the organoid matrix. The UPLC-MS/MS octreotide assay was validated for a first-in-human clinical trial⁵⁴ and herein adapted.

Calculation of intraorganoidal concentration and organoid uptake ratio

The intraorganoidal concentrations were calculated based on the approximated organoid volume after UPLC-MS/MS quantification of the respective lysis concentrations. For this purpose, the organoids were considered to be spheres with a radius of 100 µm. The concentration in the organoid before lysis was then calculated by multiplying the measured concentration in the lysis volume by the dilution factor. For all measurements, the concentration in empty but otherwise equally treated wells was determined, and the mean of that background subtracted if relevant.

The organoid uptake ratio was calculated and then correlated with the reported brain-to-plasma ratios *in vivo*. With the approximation, that:

$$\frac{\text{intraorganoidal concentration}}{\text{incubation concentration}} \approx \frac{\text{brain concentration}}{\text{plasma concentration}}$$

Therefore, at each time point after steady-state concentration was achieved, the mean intraorganoidal concentration was divided by the respective incubation concentration at that time point. These means were used as the replicates for subsequent correlation as described in the respective section. The reported *in vivo* ratios of either brain-to-plasma or CSF/unbound brain-to-free plasma concentration were used to calculate the mean with respective error. Unbound plasma concentration was determined based on the respective protein binding to calculate the unbound partition coefficient. If all values were reported with their respective standard deviation (SD), error propagation was used to calculate the error of the mean. If error values were not completely reported, the error was approximated as the standard deviation of the mean.

***In silico* BBB permeability prediction**

For the herein tested set of drugs, the respective BBB permeability predictions of four readily available *in silico* tools were determined. These were: quantitative predictions of BBBper (<https://bbbper.mdu.ac.in/>,⁵⁵) and logBB-Pred (https://ssbio.cau.ac.kr/software/logbb_pred/,⁵⁶) as well

as binary predictions by ADMETboost (<https://ai-druglab.smu.edu/admet>,^{57,58}) and SwissADME (<https://www.swissadme.ch/>,^{59,60}).

In vivo-in vitro and in vivo-in silico regression analysis

Regression analyses were performed using R version 4.3.1 (R Foundation for Statistical Calculations, Wien, Austria). For all regression analyses the untransformed correlations and the natural logarithm transformations (on one or both axes) were calculated and compared. Residuals, homoscedasticity, normal distribution and linearity were analyzed using the supporting QQ-plots, residuals vs fitted values, scale-location-diagram and Cook's distance or residuals vs index (Deming).

Because both, the organoid uptake ratios and the literature values were subject to uncertainty, a Deming-regression was performed using the Deming-package. The organoid uptake ratio replicates were used to calculate the mean and SD, to ensure equal weighting. For literature ratios x, not all replicate values were available, so the transformed standard error $\log(\Delta x)$ was estimated as follows:

$$\log(\Delta x) \approx \frac{\Delta x}{x}$$

For repotrectinib the CSF of only one volunteer was reported. The missing SD for the human and primate correlation was calculated using linear regression imputation based on the remaining data of the respective regression.

The 95% confidence intervals for both types of uncertainty were calculated using nonparametric bootstrapping (R=1000 replications).

For the regressions involving values without error (*in silico* tool values), weighted least squares regression were performed calculating 95% confidence intervals with build-in functions. The weights were defined as follows:

$$w = \frac{1}{\Delta y^2}$$

And for natural logarithm transformed values:

$$w_{log} = \frac{1}{\left(\frac{\Delta y}{y}\right)^2} = \frac{y^2}{\Delta y^2}$$

where w (and w_{log}) represents the statistical weight assigned to each data point in the regression, y the predicted (dependent) variable, and Δy the standard deviation of y.

The regressions were evaluated using the regression coefficient R^2 , which is calculated as the squared Pearson correlation coefficient. Because Deming regression does not have an associated R^2 -type measure, the Pearson correlation coefficient was used as a proxy for linear association strength reported as pseudo- R^2 .

Data analysis, statistical methods and illustrations

The Waters TargetLynx V4.2 software (Waters, Milford, MA, USA) was used for quantification with UPLC-MS/MS. This was based on $1/x^2$ -weighted linear regressions of the analyte response versus the respective IS response. The resulting calibration curve was used to quantify the study samples. GraphPad Prism was used for standard data visualization and statistical analysis, as indicated on the respective figures. Significances were displayed as follows: $p \leq 0.0001$ ****; $p \leq 0.001$ ***, $p \leq 0.01$ **, $p \leq 0.05$ *, p -values over 0.05 were considered not significant. ChemDraw (version 23.1.2) was used to draw the chemical structures and calculated clogP. Microsoft Excel and PowerPoint (Mountain View, CA, USA) were used for data processing and visualization respectively. Figures were created with adapted illustrations from Smart Servier (<https://smart.servier.com/>), licensed under CC BY 4.0 (<https://creativecommons.org/licenses/by/4.0/>) and illustrations created in BioRender (Bay, C. (2026) <https://BioRender.com/yaevw7j>), including the graphical abstract.

Results

Evaluation of 3D BBB organoid architecture

The morphology of the cells and their overall organoid architecture were evaluated in detail over the course of the culture time. Therefore, the immunofluorescence and staining protocols were optimized to include the organoid core, with longer incubation times and methanol clearing. Although simultaneous staining with different CellTracker™ dyes would have been preferable, CellTracker™ Deep Red exhibited superior properties compared to the other tested CellTracker dyes (Green CMFDA, Violet BMQC, VivoTrack 680 near infrared), particularly in terms of even distribution throughout the cells over time. Therefore, only this dye in combination with effective CD31 staining of BCEC was used. The architecture of the organoids was imaged in depth over the course of the culture: Fig. 1 shows the organoids from days 2 to 5, with emphasis on the hCMEC/D3 coverage. Detailed images of the astrocyte and pericytes on day 3 are shown in Fig. 2A-D, remaining time points can be found in detail in Supplementary Fig. 1. The morphology of the astrocytes and pericytes was harder to depict after day 4, based on the uneven CellTracker™ staining. The majority of organoids demonstrated correct architecture, while some organoid preparations showed astrocytes on the outside. However, an endothelial layer was present beneath these outside astrocytes (see Supplementary Fig. 2). Additionally, the expression of the crucial BBB hallmarks (ZO-1 and P-gp) and the collagen IV matrix were verified (Fig. 2E).





Figure 1: Representative CLSM images of the organoid architecture over culture time from day 2 to day 5 after assembly. The staining strategy is shown on the right. hCMEC/D3 cells were stained with a CD31-antibody (green). Cell nuclei are labeled with DAPI (blue). Left panel: Organoid architecture from day 2 to day 5. Pericytes or astrocytes were stained with CellTracker™ Deep red as indicated on the top. Orthogonal views of the z-stack are shown over and left side of the organoid z-slice, with DAPI and CD31 staining, as well as in combination with the CellTracker™ staining of the two different cell types. All images are representative for at least three independent organoid preparations. Scale bars were not included to maintain clarity. Illustrations were taken and adapted from Smart Servier for this figure.




Figure 2: Representative CLSM images of the detailed organoid architecture and cell morphology on day 3. All nuclei were stained with DAPI (blue). Either astrocytes or pericytes were stained with CellTracker™ (red). hCMEC/D3 cells were labeled with anti-CD31 immunofluorescent staining (green) and BBB hallmarks P-gp, ZO-1 and Collagen IV immunolabeled in magenta. **A** Organoids with stained astrocytes (red) and hCMEC/D3 (green), on the left side z-slices with the respective channels are shown and on the right side the corresponding z-projections. **B** Organoids with stained pericytes (red) and hCMEC/D3 (green), on the right side z-slices with the respective channels are shown and on the left side the corresponding z-projections. **C** Detailed view of the astrocytes in the organoid with splitted fluorescence channels. Lowest panels show magnification of the white rectangle, to highlight astrocyte process with end in contact with BCEC. **D** Detailed view of the pericytes in the organoid with splitted fluorescence channels. Lowest panels show magnification of the white rectangle, to highlight

cell elongations. **E** Representative immunofluorescence images of organoids (from top to bottom): P-gp immunostaining z-slice, magnification of outer organoid edge and a z-projection; ZO-1 immunostaining z-slice, magnification of outer organoid edge and z-projection; collagen IV immunostaining four ascending z-slices. All scale bars = 100 μ m, except in magnifications of **C** and **D** scale bar = 20 μ m. All images are representative for at least three independent organoid preparations with each at least three organoid images per experiment. Cell illustrations taken and adapted from Smart Servier.

Evaluation of apoptosis during culture by Cas3 staining

Firstly, the average size (measured as circumference) was determined over time. As depicted in Fig. 3A, the organoids did not grow significantly during the first 5 days, compared to day 2 after assembly. Only on day 6, the circumference was significantly larger. The extent of apoptosis was visualized within the relevant time frame with preferred architecture from day 2 to day 4 using Cas3 immunofluorescent staining. As shown quantitatively in Fig. 3B and with representative images in Fig. 3C, the apoptosis decreases after an initial peak on the day after generation. Over time, the Cas3-positive regions appear to move closer to the surface region of the organoid. Based on these results in combination with the architecture over time, day 3 was selected as the optimal time point for experiments.




Figure 3: Evaluation of organoid size and apoptosis over time. **A** Organoid circumference from day 2 to day 6, shown as mean $\pm$ SD of at least 18 individual organoids from four independent experiments. Significant enlargement at day 6, one-way ANOVA with Dunnett's posthoc test compared to day 2. **B** Share of Cas3 positive region between day 2 and day 4. Depicted as mean $\pm$ SD of at least eleven individual organoids from at least three independent experiments, normalized to day 3 of each experiment. Each point represents one organoid. Statistical analysis with one-way ANOVA with Turkey's correction for multiple testing comparing all groups with each other was performed. **C** Representative CLSM images of Cas3 immunofluorescent staining. On each day an organoid is shown with z-slice and one enlargement as indicated with the white rectangle. Images were processed equal for comparison.

D-Tyr(Me)Orn demonstrates modular paracellular tightness of organoids

Our previously published analytical assay with the established paracellular marker D-Tyr(Me)Orn⁵⁰ was validated in the organoid matrix, enabling its use in analyzing the integrity of organoids (Supplement Table S2).

To modify the paracellular integrity of the organoids, the cell-to-cell connections were compromised using different modulators: VEGF, adenosine, trypsin, EGTA and EDTA. This pretreatment significantly reduced the amount of the paracellular marker inside the organoids (Fig. 4A-D) indicating an increased washout of D-Tyr(Me)Orn with reduced tightness of the organoids in our experimental setting that requires six washing steps for the required sensitivity of drug uptake quantification. These results are counterintuitive, so we investigated the washout of two small fluorescent compounds using the same settings as before, but with a detection method that has a higher dynamic range: (1) Cy5, a highly hydrophilic marker, which can only reach the inner part of the organoid paracellularly and (2) hypericin, a highly lipophilic compound which can penetrate the endothelial cells via the plasma membrane. The respective distribution of the two marker compounds was evaluated with CLSM (Fig. 4G). This revealed a cell staining with the lipophilic fluorescent hypericin, while Cy5 was mainly found in the presumed extracellular space and next to nuclei showing signs of apoptosis verifying the different routes of uptake into the organoids. Quantifying the fluorescence after different washing steps revealed a higher fluorescence of Cy5 in the wash solutions in the VEGF-pretreated group. However, this difference was only significant in the third washing step (Fig. 4E). In contrast, the washout of the lipophilic compound hypericin did not increase in the VEGF-pretreated group, but was even lower in the first washing step after VEGF incubation (Fig. 4F).




Figure 4: Evaluation of paracellular integrity of the organoids. Cell connections were compromised with the indicated pretreatment **A** 20 or 200 ng/mL VEGF for 4 h, **B** 1 and 10 μM adenosine for 1 h, **C** 5 mM EGTA or 0.5 EDTA solution for 4 h **D** trypsin solution diluted 1:10 for 1 and 10 min after the six washing steps as developed for the UPLC-MS/MS setup. All pretreatments significantly reduced the intraorganoidal concentration of D-Tyr(Me)Orn compared to untreated organoids. Data presented as mean ± SD. Probable outliers were removed with GraphPad Prism. Each point represents an individual organoid from three independent experiments with each at least four organoids. **E** Accordingly, the fluorescence of Cy5 in the wash solution for washing step 3 was significantly higher in the VEGF pretreated group, **F** while the amount was reduced for the lipophilic marker hypericin in washing step 1. **G** Cy 5 and **H** hypericin were also visualized under the fluorescent microscope. Respective structures are depicted on top. These two markers showed a distinct distribution in the organoids (both red): hypericin stained the cells and Cy5 was contained to the extracellular space. Representative z-slices of organoids of three independent experiments, and respective detailed presentation. Cell nuclei stained with DAPI (blue). Scale bar = 100 μm. All statistical analysis were performed with one-way ANOVA with Dunnett's post-hoc test.

Experimental setup for UPLC-MS/MS quantification of drug uptake in organoids

Quantification on single organoid level using UPLC-MS/MS was challenging due to the difficulty of measuring low concentrations in a small number of cells. Transfer steps should be avoided due to the potential for disruption of the barrier. This required an experimental setup with easy access for washing, feasible for automation. Based on the use of spheroid plates, the organoid generation and whole drug exposure until lysis could be performed in one format (Fig. 5). Excessive washing is required due to the tiny intraorganoid volume available for drug uptake in combination with expected low permeation through the hCMEC/D3 layer and the high concentration of substance in the incubation solutions. Additionally, to avoid losing organoids when the solution is removed after incubation and during each washing step, a residual volume of 10 μ L must be left in the wells. Six washing steps ensured the required reduction of the background caused by remaining volume of substance solution in the wells (~10 μ L remaining, wash with 150 μ L) resulting in the possibility to detect intra-organoid concentrations of 1% of the incubation solution. This protocol resulted in an acceptable loss of ~5% of the organoids per plate (39 plates with a total of 2,682 organoids, 154 organoids were lost; with a mean loss of $5.5 \pm 4.0\%$ per plate).

A particular challenge for analysis was the organoids resistance to lysis due to the strong cellular and extracellular connections. The organoids were resistant to basic and acidic lysis, organic solvents, vigorous mixing, and ultrasound, in accordance with collagen expression (Fig. 2E). The goal was to completely disassemble the organoids and completely lyse cells for a reproducible lysis protocol and accurate quantification. The final protocol involved enzymatic digestion (1 h collagenase IV and 1 h trypsin/EDTA solution) followed by ammonia lysis. This achieved complete dissolution of the organoids (Supplementary Fig. S3).




Figure 5: Experimental setup for UPLC-MS/MS assay in 3D BBB organoids. Schematic overview of the organoid assay for UPLC-MS/MS quantification. Organoids are generated directly in the coated spheroid plates and incubated with the respective drug on day 3. After incubation, organoids are washed 6 times and digested with collagenase IV and trypsin. After ammonia lysis, the IS is added. Then, the samples are transferred to a new plate and subjected to the respective sample preparation and UPLC-MS/MS quantification. Created with adapted illustrations from Biorender and Smart Servier.

Correlation of organoid drug uptake with *in vivo* BBB permeability data for evaluation of the translational relevance of the 3D BBB organoid model

All drug quantifications were based on verified calibration curves using QC samples in the organoid matrix (see Supplementary Table 3 for representative QC results). Additionally, the stability of the drugs during the organoid lysis was confirmed. The concentration of the drugs in the organoid was then determined concentration- and time-dependent, as depicted in Fig. 6, A. A time-dependent assessment is necessary to identify the relevant concentration equilibrium for accurate organoid uptake ratio calculation. Concentration-dependent assessment is required to identify nonlinear effects, such as transport saturation. All uptakes were performed in three independent experiments. Not all incubations and time points resulted in measurable organoid concentrations. Values were accepted for downstream analysis if at least seven individual organoids from two independent organoid preparations were quantifiable. For octreotide, the concentrations in the organoids equaled the background concentrations and were therefore interpreted as negligible organoid uptake. This zero-point was not used for correlation and only included in the following plots for visualization. Overall, organoid concentration was linear to increasing incubation concentration. Saturation of uptake was achieved for all drugs within the observed time frame. Steady state was presumed, when there was no significant concentration increase between the time points (see Supplementary Table S4). After reaching steady state, the ratio of the mean organoid uptake concentration to the respective incubation concentration was calculated for

each time point (= organoid uptake ratio). These ratios, each based on at least ten individual organoids, were used as replicates for the correlation with reported *in vivo* brain-to-plasma ratios (Fig. 6B). The *in vivo* data can be seen in detail in Table 3. Either the brain tissue-to-total plasma ratio or the unbound brain- or CSF- to-unbound plasma ratio was used (please refer to the discussion for a detailed description of the literature data). Concentrations too close to the measured background were excluded to avoid artifacts. Reduction of viability and cytotoxic effects were evaluated for all drugs used (Fig. 6C). The quality of the correlation was determined using Deming regression (Fig. 6D-F). A comparison of the mammalian correlations performed with and without transformation can be seen in Supplementary Fig. S4. Based on normality diagnostic plots, a transformation using the natural logarithm of both axes was selected for the final correlation (see Supplementary Fig. S5). This resulted in a pseudo R^2 of 0.64 for the Deming regression between organoid uptake ratios and the complete mammalian data set for *in vivo* brain-to-plasma ratios (Fig. 6, D). Sub-analysis with the reported primate data provided a pseudo R^2 of 0.81 (Figure 6, E), and regression solely based on human data resulted in a pseudo R^2 of 0.82 (Figure 6, F).




Figure 6: A Concentration-time profile of the quantified drugs in the organoid. These were used to determine the steady state time and to calculate the respective organoid uptake ratios for the correlation. Data depicted as mean $\pm$ SEM of at least seven organoids from at least two independent organoid preparations. **B** Correlation of organoid uptake ratios with reported *in vivo* brain-to-plasma ratios. The quantified drug concentrations in the organoid were used to calculate the ratio to the incubation concentration (organoid uptake ratio). These are depicted against the reported *in vivo* brain-to-plasma ratios (Table 3). Data is shown as mean $\pm$ error calculated as described in the method section. Based on logarithmic axis, the zero data point of octreotide cannot be depicted and was inserted afterwards for conceptual visualization. **C** Viability (ATP) and Cytotoxicity (LDH) after incubation with the highest used concentration for the longest observed time point. Mean $\pm$ SD of at least three replicates. Each point represents an individual organoid. **D** Deming regression of the measured organoid uptake ratios with reported mammalian *in vivo* brain-to-plasma ratios and **E** with only the reported primate *in vivo* data and **F** only the human *in vivo* data. The correlations were performed using natural logarithm-transformed data. Respective pseudo R^2 and the 95% confidence interval are depicted. The Deming regression calculated the insecurities of both axes. Data points represent the mean of the ratios of the individual drugs, the error values were transformed as described in the method section.

Regression of the *in vivo* BBB permeability data set with results from *in silico* BBB prediction tools reveals absent linear correlation

For the selected drug set, the BBB permeability predictions of four *in silico* web tools were determined and correlated with the researched *in vivo* data set. Two of the tools provided quantitative results: the BBB Score [%] of ADMETboost and logBB-values of the logBB-Pred tool (Fig. 7A and B). As performed for the correlation with the organoid uptake data, natural logarithm transformations were performed, and the best hits were presented (Fig. 7C and D, comparisons of direct and transformed correlations are in Supplementary Fig. 4, transformed diagnostic plots are in Supplementary Fig. S5). Because only the *in vivo* data had a reported error, a weighted regression was performed. However, no linear correlation was seen for the selected drug set with either tool (R^2 of 0.06 and 0.13). The binary results (BBB permeable/non-permeable) of SwissADME and BBBper also did not result in a meaningful pattern (Fig. 7E and F).




Figure 7: Correlation of reported *in vivo* brain-to-plasma ratios with the results of four *in silico* tools for BBB permeability prediction. The *in vivo* brain-to-plasma ratios summarized in Table 3 are depicted against the quantitative results of **A** ADMETboost (BBB Score) and were subject to **B** a weighted regression. **C** Similarly, the logBB-Pred (logBB-value) were depicted against the *in vivo* brain-to-plasma ratios and **D** evaluated with a weighted regression. Both depicted as the mean with 95% confidence interval. Transformations were performed with natural logarithm. Comparative presentation of the binary BBB permeability prediction **E** of SwissAdme and **F** BBBper tools. Based on logarithmic depiction octreotide was inserted afterwards for conceptual visualization. Data are represented as mean $\pm$ SD. For error calculation of the regressions, please refer to the method section. Note that the axes were reversed for the regression to fit the standard definition.

563

564

Discussion

Predicting human BBB permeability is crucial for assessing the suitability of drug candidates in addition to identifying candidates with limited permeability for avoiding CNS side effects in malignancies not associated with the CNS. Unfortunately, determining BBB permeability is challenging even in the clinical settings, due to the restricted access to human CNS samples. Animal models show partly large discrepancies especially for P-gp substrates⁵⁻¹⁰. Although *in vitro* models lack pharmacokinetic recapitulation, they can be composed of human cells only. Complex models based on different cell types of the neurovascular unit have been shown to be relevant in pathophysiological modeling^{61,62}. In general, accessibility to the basolateral compartment, and therefore to the sample behind the BBB, decreases as complexity increases⁶²⁻⁶⁴. For example, in complex BBB-on-a-chip-models, the readout is restricted to fluorescent substances⁶³ or requires the application of pressure⁶⁵. However, accessibility for quantification is a main quality criterion for pharmacological analysis. While larger constructs for delivery strategies can be easily labeled, dependency on fluorescence hinders the evaluation of small molecules, because fluorescent tags severely alter their physicochemical properties.

The 3D BBB organoid model is accessible for UPLC-MS/MS analysis

Previous readouts in the 3D BBB organoid model used herein were mainly based on imaging analysis with fluorescence for marker substances, targeting constructs or 2D MS technique like MALDI for exemplary uptake evaluation of two drugs^{19,20,48,49}. However, not all molecules of interest can be observed with fluorescence read-out and MALDI has currently limited resolution (30-50 μm ^{19,49}), is not trivial, requires sample slicing and not all analytes ionize sufficiently. In contrast, 1D MS such as UPLC-MS/MS, is the gold standard for clinical drug quantification.

To our knowledge a validated assay for the quantitative analysis with simple and higher-throughput-MS has been lacking. The only previous 1D MS assay for BBB organoids was a binary evaluation as verification for an *in silico* tool without relation to the respective limit of quantification or detection⁶⁶. Due to the absence of quantitative drug uptake measurements in such organoids we established an easy, reproducible and adaptable framework for quantifying a wide range of drugs in 3D BBB organoids. We

investigated and identified optimal organoid culture and handling conditions. Using commercially available plates, the organoid generation is faster, the risk of contamination reduced, and the plate precoating increases reproducibility. These plates allow for an easy medium change with minimal organoid loss and eliminate the need for transfer steps. This ensures compatibility with automation, when either a tilting platform or angled pipetting is available. The major bottleneck of this high-throughput assay is the LC-MS/MS quantification method development with sufficient (very low) limits of quantification. However, most small molecules (and peptide) quantifications are accessible by standard sample processing techniques like protein precipitation using organic solvents and reverse-phase chromatography, as was performed for most of the drugs in this study. Exceptions are the liquid-liquid extraction for fluoxetine and the HILIC separation for D-Tyr(Me)Orn, also delivering sufficiently low quantification limits. The developed options provide a blue print for preparing samples for a wide range of analytes.

The investigation of two fluorescent model substances (Cy5 and hypericin) verified that these drugs are not only attached to the outer cell layer, but indeed inside the organoid structure. These substances also demonstrated a strong difference between lipophilic and hydrophilic distribution within the organoids. Of note, the whole organoid lysis results in the quantification of drugs in the organoids, as well as adsorbed to and in the BCEC. However, the same is true for tissue quantification *in vivo*. Drug-specific variations can occur, especially in low-permeable substances, depending on the effects of perfusion and washing, which could potentially result in *in vitro-in vivo* artifacts.

The 3D BBB organoid model shows favorable architecture and viability on day 3 after generation

The organoids were verified to be comparable to those in previous publication after the described culture adaptations like using an orbital shaker, as well as the ready-to-use pre-coated plates. This was performed with CLSM with respect to architecture and crucial BBB hallmark expression. While previous investigations mainly focused on the overall architecture, we observed the specific morphology of astrocytes and pericytes in detail and over time. We therefore optimized the staining protocols for in detail imaging, including the selection of the most suitable dye and addition of sample clearing.

Due to the inverse and spherical architecture of the organoids, they cannot develop true BBB structure, which requires pericytes to wind helically around the vessel^{67,68} and the coverage with astrocyte end feet

over the other two cell types^{69,70}. However, the presence of elongations of both cell types demonstrates that they are viable cells with a morphology that resembles *in vivo* cells and that they both interact with the BCEC. Organoid models do not exhibit the physiological architecture of the microvasculature, unlike self-vascularizing models in microfluidic systems^{63,65}. Nonetheless, compared to these models, the organoids used here show a higher accessibility to the basolateral compartment by whole organoid lysis, while more closely recapitulating free cell-type interaction than Transwell® models or microfluidic systems without vascularization. A meaningful future comparison would be a direct performance comparison of organoids with both kinds of microfluidic models – simple BCEC layers with other cell types for example in matrix gel⁷¹ and self-vascularized structures⁶⁵.

BCEC are the core of each BBB model and generally benefit from additional differentiation time in the final BBB model setup^{63,72}. The aim is to achieve a tight monolayer. The outer surface of the organoids appeared to be smoother on day 3, possibly indicating closer cell contact. After day 4 a tendency for more CD31+ cells on the cell layer was identified, possibly representing the formation of a multilayer to some extent. In general, hCMEC/D3 exhibits contact inhibition in 2D monoculture⁷³, and previous publications on organoids did not observe an increase in overall organoid size²⁰. However, we observed an increase in organoid circumference, which was most likely due to an increase in the number of pericytes over time. Because all cell types exhibited positive Ki67 staining for proliferation⁴⁹, a complete contact inhibition of the hCMEC/D3 in the organoids could not be assumed. Therefore, any sign of a multilayer hCMEC/D3 was closely observed, although this was hampered by the strong CD31 signaling. Additionally, viability was assessed by evaluating the amount of apoptosis. The main peak on day 2 and the subsequent decrease can most likely be attributed to the stress of generating the organoids, which includes detaching the adherent cells. Cas3 staining was sufficient for our general evaluation, however, we want to note that Bell and coworkers have developed a precise and validated toxicity screening based on hematoxylin staining for these organoids⁴⁹. Importantly, not all standard *in vitro* assays for viability or cytotoxicity assessment we tested were sensitive enough for single organoids, highlighting the need for evaluation in the used *in vitro* model and inclusion of negative and positive controls.

Eventually, in combination with the evaluation of the architecture and the hCMEC/D3 monolayer, day 3 was identified as the optimal time point for analyses, because it offered the best balance between the

correct cell morphology, complete and smooth endothelial layer, constant size, apoptosis and existence of a single endothelial layer.

The performed culture adaption had no impact on the previously reported correct expression patterns of ZO-1 and P-gp, which is important due to the significant impact of TJ and efflux transporters on BBB permeability. However, the mere expression of a TJ marker is not a sufficient confirmation of functionality, because TJ require correct localization and architecture^{74,75}. ZO-1 expression was also observed in the cytoplasm, as is often the case with hCMEC/D3 while pure expression at the cell corners would be more representative of physiological conditions^{20,76,77}. Final conclusions about barrier properties can only be drawn from a functional evaluation.

The 3D BBB organoid model shows functional barrier properties

In previous studies, TJ modulation with VEGF or histamine in 3D BBB organoids resulted in a higher intraorganoidal signal of fluorescently tagged, high-molecular-weight molecules^{20,61,78}. There was no relevant uptake of these paracellular markers in intact organoids, nor was there any size-dependency observed between 4 to 70 kDa⁴⁸. Considering the highly restrictive nature of the BBB as well as the small size of average drugs, macromolecular substances are not suitable to evaluate subtle but relevant BBB impairment. However, for smaller markers, the literature is contradicting: the organoids were shown to be impermeable to larger molecules without modulation of the barrier, but free fluorescein isothiocyanate (FITC) was able to diffuse into the organoids, without significant difference compared to those organoids without BCEC⁴⁸. Recent results also showed a basal uptake of Lucifer Yellow in intact organoids, which in contrast was increased upon treatment with TNF- α and INF- γ ⁷⁹. Similarly, difference in the incubation solution concentration of fluorescein was shown between different organoids with iPS-derived endothelial cells⁸⁰. Similar to FITC and Lucifer Yellow, we observed low basal uptake of Cy5 and D-Tyr(Me)Orn. The latter is a previously developed dipeptide paracellular marker that can be measured with high sensitivity using UPLC-MS/MS and is highly discriminative for TJ status due to its small size⁵⁰. Interestingly, we did not observe an increase in the intraorganoidal concentration of the marker substance when we modulated the cell connections by disruption of the calcium-dependent junctions with EGTA/EDTA, modulating the TJ with adenosine and VEGF, or

degrading proteins with trypsin. In contrast, these treatments in our assay resulted in decreased intraorganoidal D-Tyr(Me)Orn. We hypothesize that the discrepancy's for small markers may be due to wash-out phenomenon's: The small marker D-Tyr(Me)Orn can be washed out more efficient in the compromised organoids masking or even reversing the uptake into the organoids during incubation. For Cy5 – the fluorescent pendant to D-Tyr(Me)Orn– this results in an detectable increased amount of marker in the washing solutions. However, small differences are hardly detectable due to the minimal amount of substance in the organoids compared to that in the remaining uptake solution before washing. Therefore, differences would only be visible after the remaining uptake solution is sufficiently diluted by washing steps. This is in line with what we observed for the fluorescent marker Cy5 with a higher amount detected in the washing solutions after VEGF treatment, that only is significant in step 3.

Interestingly, the hypericin washing solution exhibited the opposite effect. This may be due to a higher hypericin amount in the compromised organoids that is resistant to wash-out due to the high lipophilicity.

The larger marker substances, which only enter after cell connections are modulated, are more than 200 times larger, and therefore may show completely different behavior during washout. In addition, it is worth mentioning that other protocols are restricted to three washing steps^{20,48,61}, if washing steps are specified at all.

All of the assays developed herein allow for the simultaneous quantification of two analytes – one intended for the drug and one for the paracellular marker – at the single organoid level. However, D-Tyr(Me)Orn cannot be used as a threshold for organoid integrity. While D-Tyr(Me)Orn was able to identify significant effects based on the organoid integrity in the mean, the high biological variance in the untreated organoids hindered the discrimination power of the marker as a threshold on single organoid level. The basal uptake of small hydrophilic molecules (D-Tyr(Me)Orn, FITC and Cy5) must be considered, as it limits the use of small paracellular biomarkers for integrity control in such models.

The fact that hCMEC/D3 did not show a difference in permeability after EGTA treatment in the 2D Transwell[®] assay⁵⁰ and after VEGF treatment (see supplemental Figure S6), but caused reduced D-Tyr(Me)Orn concentration in the organoid model indicates a more highly developed BCEC phenotype in the hCMEC/D3 layer in the organoid model. This is in accordance with the observable higher

expression of P-gp and ZO-1 in the 3D organoid model compared to 2D models²⁰. The use of BCEC with higher *in vitro* barrier properties, including the fast-growing field of iPS derived cells could possibly further improve the integrity of 3D organoid models⁸⁰.

Drug uptake in the 3D BBB organoids correlates with *in vivo* permeability values

As the updated classification criteria for brain tumors place greater emphasis on molecular and genetic alterations, personalized and targeted therapies are becoming the focus of clinical development^{81,82}. One example is the 2026 approval of the targeted therapy tovorafenib⁸³. In light of the latest research findings linking neuronal activity and Ca²⁺ signaling to glioblastoma growth^{84,85}, repurposing of drugs is another up-to-date approach⁸⁶⁻⁸⁸. Based on these developments, we selected a set of drugs with different BBB permeabilities, including P-gp and BCRP substrates, as well as different lipophilicity values and sizes (see Table 4), in order to test the translational relevance of the organoid model.

Although quantification of drug uptake is the most meaningful pharmacological evaluation of a BBB model, it has not been previously performed in 3D BBB organoids. For evaluating the translational significance, we correlated the organoid uptake ratios on a single organoid level in equilibrium with the *in vivo* BBB permeability values of the 12 drugs with measurable concentrations and reported brain-to-plasma ratios (Table 3). We included all found mammalian brain-to-plasma ratios (exceptions listed in the limitations), to generate a mean and achieve a representative *in vivo* permeability data set, resulting in the high standard deviation seen for some drugs. The correlation of the organoid uptake ratios with the reported *in vivo* values revealed a strong correlation in the Deming regression accounting for uncertainties in both variables. This results in a qualified NAM, indicating its suitability for predictive BBB permeability ranking.

The sub-analysis with pure primate and human data resulted in even higher regression coefficients. Although a direct comparison between these regression analyses is not possible, based on the deviating number of drugs with available *in vivo* data, a tendency of this fully human organoid model to better correlate with human data can be observed.

Selecting the transformation with the natural logarithm allowed for a proportional consideration of values across multiple orders of magnitude. Otherwise, high values would have a disproportionate

influence on the correlations (correction for scale imbalance). This transformation also corrects for a higher standard deviation, which often increases with the magnitude of the measured values (correction for heteroscedasticity). These corrections are clearly visible in the quantile-quantile plot (QQ) and residual plots that fulfill the criteria for linearity, normal distribution, homoscedasticity and equal weighting. With this regression, it becomes possible to perform predictions for drugs quantified in the organoid, despite that the BBB organoid model can't fully represent physiological states of the BBB due to the lack of dynamic blood flow, as well as an inability to recapitulate the complex architecture, from which the unique features of this barrier arise.

The drug quantifications showed a high interorganoidal variance, at least partly due to the already high size variation between the organoids of approximately 10% adding to the expected biological variation and organoid formation. This cannot be corrected by the standardized volume approximation, but in part be counterbalanced by the possibility to perform more replicates based on the measurement on single organoids. Previous publications often considered organoids as biological replicates^{20,49,61}. Based on the high variance observed here, multiple organoids from at least two independent preparations were regarded reliable for drug quantification. Additionally, to reduce the influence of interorganoidal variance, the mean of single time and concentration points in steady state was used for correlation analysis.

Selecting physiologically relevant concentrations resulted partly in uptake amounts below the quantification limit. Additionally, low concentrations within the organoid may be obscured by the background (e.g., uptake with 180 ng/mL larotrectinib results in a background of ~ 70% of signal; 1,800 ng/mL in a background of ~ 10% of signal). Increasing the number of washing steps or the time can increase the probability of washing artifacts and diffusion. Six washing steps were selected as a trade-off between reducing background and washout time. All drugs except octreotide were measurable above the background level, consistent with the negligible brain penetration of this octapeptide, highlighting the ability of this NAM to model low/no brain permeability.

In contrast to the organoid *in vitro* model, the *in silico* models used herein did not show a correlation with the *in vivo* data. However, at least two of the models (chemical descriptor-based) are among the top-ranked current tools⁸⁹. The quality of all trained models depends on the quality of the training

dataset. As discussed in the limitations, the BBB permeability data is of poor quality, resulting in lower information content. Larger data sets are often binary, or use thresholds for combination with quantitative data and are biased toward permeable drugs with lesser entries of non-permeable substances. This strategy depends heavily on the selected threshold and naturally neglects relevant drugs with low permeability and low effective concentration. This makes the training of quantitative models extremely difficult^{57,89}. Additionally, they often incorporate the physiochemical properties, which regularly fail to truly determine the BBB permeability².

Limitations:

One limitation of our model is the variance in the regression which indicates uncertainty in these predictions, reflected in the confidence intervals and based on the interorganoidal variance.

A general limitation in BBB research is the current data availability and variation in acquisition. Brain-to-plasma ratios are not standardized and can differ in regard to:

1) Method of sampling. Typically, they are measured by quantifying the brain tissue concentration and the total plasma concentration (B/P or as partition coefficient $K_{p,brain}$). For substances with high platelet incorporation, determination in whole blood is more appropriate (see e.g., temsirolimus). Since only the unbound fraction of a drug can reach the target, the unbound fraction ratio (B_u/P_u or unbound partition coefficient $K_{p,uu,brain}$) was proposed as a more insightful parameter⁹⁰. Quantifying unbound brain concentration or the extracellular fraction is not trivial. It can also be determined in different ways, either by technically challenging microdialysis^{91,92} or by calculation with the beforehand identified tissue binding percentage. Although not always identical, the concentration in the CSF is used as an approximation of free brain concentration^{90,91,93,94}.

2) Time of sampling. Partition coefficients are determined either in steady state or after a single dose with the AUC. Unfortunately, these ratios are not always established in a time-independent manner: quantification of the B/P ratio after a single dose on a single time point depends highly on drug-specific pharmacokinetics and, therefore, on the selected time point.

3) Specie and pathophysiology. Obviously, brain-to-plasma ratios are more comparable when evaluated in healthy subjects. However, the ratios are often determined in the relevant disease model, which

frequently affects the BBB. Most human data are collected from patients included in clinical studies, as seen here with the CSF samples for repotrectinib and lorlatinib. Therefore, and based on the smaller assumed effect on CSF concentrations from a partly opened BBB, we included these data for our correlation analysis. Data derived from tumor tissue was only included if it was mixed with total brain tissue or if it was shown to have no differences compared to healthy brain tissue. The exception was temsirolimus, for which tumor tissue data were the only available tissue concentrations. For olaparib, mice with tumors showed comparable results to healthy macaques⁹⁵. The authors presumed this amount to be negligible with no true brain penetration, consistent with quantifications in rats⁹⁶. In contrast, human tumor tissue showed a high concentration of olaparib with large variability, probably due to BTB⁹⁶.

Ulixertinib exhibited low brain concentrations in healthy and tumor tissue of mice, resulting in a brain-to-plasma concentration of 0.0176⁵³. The first results of a clinical trial, presented in a poster, show higher brain concentrations in tumor patients. The CSF-to-unbound plasma concentration was 1.33 with high discrepancies in the tumor's bound ratios (enhancing region: 0.5; non-enhancing region: 0.2). However, these results are still much larger than those observed in rodents⁹⁷. This discrepancy may be due to species differences often observed for P-gp substrates⁵⁻¹⁰.

4) Inclusion of relevant metabolism. While we did not observe relevant generation of the active metabolites of fluoxetine and temsirolimus in the organoid model, the amount of norfluoxetine is included in the reported *in vivo* brain permeability. We therefore used these sums as approximations for fluoxetine alone.

Ultimately, all these deviations may result in discrepancies in the reported brain-to-plasma ratios for a drug. Improved *in vivo* data would benefit translational correlations for performance evaluation of BBB models and training of *in silico* prediction tools.

Conclusion

This study established and validated the first UPLC-MS/MS assay for the reproducible quantification of drugs in single 3D BBB organoids. This strategy generated the first pharmacological quantitative evaluation of *in vitro*-to-*in vivo* translational relevance for drug BBB permeability in an organoid model

and qualified this strategy as a NAM for prediction and ranking of the BBB permeability of drugs *in vivo*. This NAM was demonstrated to be superior over state-of-the-art *in silico* prediction models and outperformed reported 2D BBB models. The reliable setup allows for future automation to implement this NAM into routine screening of drug candidates for CNS malignancies or to select candidates with low BBB permeability to avoid CNS side effects in toxicological characterization.

Supplementary information:

Supplement Table S1: Mass spectrometry and chromatography parameters for analyzed drugs.

Supplementary Figure S1: Representative CLSM images over culture time from day 2 to day 5 after assembly.

Supplementary Figure S2: Representative CLSM images of astrocytes located outside the organoid cover in some organoid preparations.

Supplementary Table S2: Validation results for D-Tyr(Me)Orn in organoid matrix.

Supplementary Figure S3: Representative light microscopy images of organoid lysis.

Supplementary Figure S4: Comparisons of direct and logarithm transformed correlations.

Supplementary Figure S5: Diagnostic plots for performed correlations with and without logarithmic transformation.

Supplementary Table S3: Representative quality control results for UPLC-MS/MS drug assays.

Supplementary Table S4: Statistical analysis of drug uptake in organoids over time.

Supplementary Figure S6: Clearance volume of Transwell® experiments of D-Tyr(Me)Orn for hCMEC/D3.

Extended Data 1: Reproducible code for regression.

Extended Data 2: Regression data.

Author Contributions: Conceptualization, CB, MS, GB, JW, JB; Formal analysis, CB; Funding acquisition, CB, MS; Investigation, CB, EM, CS, MK, JC; Methodology, CB, JW, MS, JB, CS, GB;

Project administration, JB, JW, MS; Resources, JB, JW, PU, JCS; Supervision, CB, JW, MS, JB, GB; Validation, CB, MS, JW, GB, JB, CS; Visualization, CB, CS; Writing – original draft, CB; Writing – review & editing, JB, JW, MS, GB, CS, EM, PU, JCS, MK, JC.

Funding: This work was supported by the “Krebs-und Scharlachforschung Mannheim” and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – Project ID 404521405, SFB 1389 – UNITE Glioblastoma, Work Package C01. GB was supported by the Physician Scientist and the Olympia Morata program of the Faculty of Medicine of Heidelberg University.

Availability of data and materials: The data supporting the conclusions of this article is included within the published article. The data for the regression curve is made available with this manuscript in extended data file 2, together with an in-detail reproducible R Markdown file in extended data 1.

Acknowledgments: We thank Kevin Steimel for excellent technical assistance and the Heidelberg Nikon Imaging Center for support with CLSM.

AI Statement: Perplexity AI was used to support literature research <https://www.perplexity.ai/> (last accessed 11.09.26), Gemini and DeepL Write for improving the English in some sections and Copilot for streamlining of the R programming. The authors reviewed all suggestions and take full responsibility for the final content.

List of abbreviations: ACN: acetonitrile; AGMTM: Astrocyte Growth Medium with all supplements; AJ: adherens junctions; ALK: anaplastic lymphoma kinase; AUC: area under the curve; BBB: blood brain-barrier; BCEC: brain capillary endothelial cells; BCRP: breast cancer resistance protein; BSA: bovine serum albumin; BTB: blood-tumor barrier; Cas3: cleaved caspase 3; clogP: calculated logP; CLSM: confocal laser scanning microscopy; CNS: central nervous system; CID: collision-induced dissociation; D-Tyr(Me)Orn: D-O-methyl-tyrosine and D-ornithine; DMSO: dimethyl sulfoxide; EGMTM: Endothelial Growth Medium 2 with all supplements; EDTA: ethylenediamine tetraacetic acid; EGTA: ethylene glycol tetraacetic acid; ERK1/2: extracellular signal regulated kinase; ESI: electrospray ionization; FA: formic acid; FBS: fetal bovine serum; FGFR: fibroblast growth factor receptor; HBSS: Hanks Balanced Salt Solution; HCl: hydrochloric acid; HHBSS: HBSS with 0.01 M HEPES; IF: immunofluorescence; IS: internal standard; K_{CA}3.1: calcium activated potassium channel; LDH: lactate

dehydrogenase; LPR-1: low density lipoprotein receptor-related protein 1; LLOQ: lower limit of quantification; MAPK: mitogen-activated protein kinase; MRM: selected reaction monitoring; mTOR: mechanistic target of rapamycin; MW: molecular weight; NaOH: sodium hydroxide; NTRK: neurotrophic tyrosine receptor kinase; MALDI: matrix-assisted laser desorption/ionization; MRP2: multidrug resistance associated protein 2; MW: molecular weight; NAM: New Approach Methodologies; NFLU: norfluoxetine; PARP: poly(ADP-ribose)-polymerase; P-gp: P-glycoprotein; PBS: phosphate-buffered saline; PM: Pericyte Medium; QC: quality control; QQ plot: quantile-quantile plot; ROI: region of interest; ROS1: proto-oncogene 1; RPMI: Roswell Park Memorial Institute; SSRI: selective serotonin reuptake inhibitor; TBME: tert-butyl methyl ether; TJ: tight junctions; UPLC-MS/MS: ultra-performance liquid chromatography tandem mass spectrometry; VEGF: vascular endothelial growth factor; ZO-1: Zonula occludens 1.

Competing interests: The authors declare no conflict of interest.

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

References

- 1 Pardridge, W. M. Blood-brain barrier delivery. *Drug Discov Today* **12**, 54-61, doi:10.1016/j.drudis.2006.10.013 (2007).
- 2 Banks, W. A. Characteristics of compounds that cross the blood-brain barrier. *BMC Neurol* **9**, doi:10.1186/1471-2377-9-S1-S3 (2009).
- 3 Sarkaria, J. N. et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. *Neuro Oncol* **20**, 184-191, doi:10.1093/neuonc/nox175 (2018).
- 4 Lockman, P. R. et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. *Clin Cancer Res* **16**, 5664-5678, doi:10.1158/1078-0432.CCR-10-1564 (2010).
- 5 Syvänen, S. et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. *Drug Metab Dispos* **37**, 635-643, doi:10.1124/dmd.108.024745 (2009).
- 6 Kido, Y. et al. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse. *Drug Metab Pharmacokinet* **42**, 100426, doi:10.1016/j.dmpk.2021.100426 (2022).

- 897 7 Zhang, W. et al. Differential expression of ABC transporter genes in brain vessels vs. peripheral
898 tissues and vessels from human, mouse and rat. *Pharmaceutics* **15**, 1563,
899 doi:10.3390/pharmaceutics15051563 (2023).
- 900 8 Verscheijden, L. F. M., Koenderink, J. B., de Wildt, S. N. & Russel, F. G. M. Differences in P-
901 glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic
902 modelling. *Arch Toxicol* **95**, 3015-3029, doi:10.1007/s00204-021-03115-y (2021).
- 903 9 Song, H. W. et al. Transcriptomic comparison of human and mouse brain microvessels. *Sci Rep*
904 **10**, 12358, doi:10.1038/s41598-020-69096-7 (2020).
- 905 10 Baltes, S. et al. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam
906 and carbamazepine by human and mouse P-glycoprotein. *Neuropharmacology* **52**, 333-346,
907 doi:10.1016/j.neuropharm.2006.07.038 (2007).
- 908 11 Wasielewska, J., Da Silva Chaves, J., White, A. & LE, O. Alzheimer's disease: Drug discovery.
909 Chapter 7: Modeling the blood-brain barrier to understand drug delivery in Alzheimer's disease.
910 (Exon Publications, 2020).
- 911 12 Uchida, Y. et al. Quantitative targeted absolute proteomics of human blood-brain barrier
912 transporters and receptors. *J Neurochem* **117**, 333-345, doi:10.1111/j.1471-4159.2011.07208.x
913 (2011).
- 914 13 Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on
915 the protection of animals used for scientific purposes; Official Journal of the European Union.
- 916 14 EMA. Guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction,
917 refinement) testing approaches; 15.12.2016;
918 [[https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-principles-](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-principles-regulatory-acceptance-3rs-replacement-reduction-refinement-testing-approaches_en.pdf)
919 [regulatory-acceptance-3rs-replacement-reduction-refinement-testing-approaches_en.pdf](https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-principles-regulatory-acceptance-3rs-replacement-reduction-refinement-testing-approaches_en.pdf); last
920 accessed 06.06.2026].
- 921 15 FDA. Roadmap to Reducing Animal Testing in Preclinical Safety Studies. (2025)
922 [[https://www.fda.gov/files/newsroom/published/roadmap_to_reducing_animal_testing_in_pre-](https://www.fda.gov/files/newsroom/published/roadmap_to_reducing_animal_testing_in_pre-clinical_safety_studies.pdf)
923 [clinical_safety_studies.pdf](https://www.fda.gov/files/newsroom/published/roadmap_to_reducing_animal_testing_in_pre-clinical_safety_studies.pdf); last accessed 15.10.2026].
- 924 16 Marshall, L. J., Bailey, J., Cassotta, M., Herrmann, K. & Pistollato, F. Poor translatability of
925 biomedical research using animals - A narrative review. *Altern Lab Anim* **51**, 102-135,
926 doi:10.1177/02611929231157756 (2023).
- 927 17 Marmol, I., Abizanda-Campo, S., Ayuso, J. M., Ochoa, I. & Olivan, S. Towards novel
928 biomimetic in vitro models of the blood-brain barrier for drug permeability evaluation.
929 *Bioengineering (Basel)* **10**, doi:10.3390/bioengineering10050572 (2023).
- 930 18 Badawi, A. H. et al. In vitro blood-brain barrier models for neuroinfectious diseases: A narrative
931 review. *Curr Neuropharmacol* **22**, 1344-1373, doi:10.2174/1570159X22666231207114346
932 (2024).
- 933 19 Bergmann, S. et al. Blood-brain-barrier organoids for investigating the permeability of CNS
934 therapeutics. *Nat Protoc* **13**, 2827-2843, doi:10.1038/s41596-018-0066-x (2018).
- 935 20 Cho, C. F. et al. Blood-brain-barrier spheroids as an in vitro screening platform for brain-
936 penetrating agents. *Nat Commun* **8**, 15623, doi:10.1038/ncomms15623 (2017).
- 937 21 Daneman, R., Zhou, L., Kebede, A. A. & Barres, B. A. Pericytes are required for blood-brain
938 barrier integrity during embryogenesis. *Nature* **468**, 562-566, doi:10.1038/nature09513 (2010).

939 22 Ben-Zvi, A. et al. Mfsd2a is critical for the formation and function of the blood-brain barrier.
940 *Nature* **509**, 507-511, doi:10.1038/nature13324 (2014).

941 23 Armulik, A., Genove, G. & Betsholtz, C. Pericytes: developmental, physiological, and
942 pathological perspectives, problems, and promises. *Dev Cell* **21**, 193-215,
943 doi:10.1016/j.devcel.2011.07.001 (2011).

944 24 Winkler, E. A., Bell, R. D. & Zlokovic, B. V. Central nervous system pericytes in health and
945 disease. *Nat Neurosci* **14**, 1398-1405, doi:10.1038/nn.2946 (2011).

946 25 Bell, R. D. et al. Pericytes control key neurovascular functions and neuronal phenotype in the
947 adult brain and during brain aging. *Neuron* **68**, 409-427, doi:10.1016/j.neuron.2010.09.043
948 (2010).

949 26 Nikolakopoulou, A. M. et al. Pericyte loss leads to circulatory failure and pleiotrophin depletion
950 causing neuron loss. *Nat Neurosci* **22**, 1089-1098, doi:10.1038/s41593-019-0434-z (2019).

951 27 Guerit, S. et al. Astrocyte-derived Wnt growth factors are required for endothelial blood-brain
952 barrier maintenance. *Prog Neurobiol* **199**, 101937, doi:10.1016/j.pneurobio.2020.101937
953 (2021).

954 28 Alvarez JI, D.-D. A., Kebir H, Ifergan I, Fabre PJ, Terouz S, Sabbagh M, Wosik K,
955 Bourbonnière L, Bernard M, van Horssen J, de Vries HE, Charron F, Prat A. The hedgehog
956 pathway promotes blood-brain barrier integrity and CNS immune quiescence. *Science* **334**,
957 1727-1731 (2011).

958 29 Cibelli, A. et al. Cx43 carboxyl terminal domain determines AQP4 and Cx30 endfoot
959 organization and blood brain barrier permeability. *Sci Rep* **11**, 24334, doi:10.1038/s41598-021-
960 03694-x (2021).

961 30 Heithoff, B. P. et al. Astrocytes are necessary for blood-brain barrier maintenance in the adult
962 mouse brain. *Glia* **69**, 436-472, doi:10.1002/glia.23908 (2021).

963 31 Sun, J. & He, Z. Interactions between astrocytes and cerebral endothelial cells in central nervous
964 system diseases. *Biomed Pharmacother* **191**, 118516, doi:10.1016/j.biopha.2025.118516
965 (2025).

966 32 Abbott, N. J., Ronnback, L. & Hansson, E. Astrocyte-endothelial interactions at the blood-brain
967 barrier. *Nat Rev Neurosci* **7**, 41-53, doi:10.1038/nrn1824 (2006).

968 33 Dohgu, S. et al. Brain pericytes contribute to the induction and up-regulation of blood-brain
969 barrier functions through transforming growth factor-beta production. *Brain Res* **1038**, 208-215,
970 doi:10.1016/j.brainres.2005.01.027 (2005).

971 34 Lippmann, E. S. et al. Derivation of blood-brain barrier endothelial cells from human pluripotent
972 stem cells. *Nat Biotechnol* **30**, 783-791, doi:10.1038/nbt.2247 (2012).

973 35 Qian, T. et al. Directed differentiation of human pluripotent stem cells to blood-brain barrier
974 endothelial cells. *Science Advances* **3**, e1701679 (2017).

975 36 Hayashi, Y. et al. Induction of various blood-brain barrier properties in non-neural endothelial
976 cells by close apposition to co-cultured astrocytes. *Glia* **19**, 13-26, doi:10.1002/(sici)1098-
977 1136(199701)19:1<13::Aid-glia2>3.0.Co;2-b (1997).

978 37 Orlidge, A. & D'amore, P. A. Inhibition of capillary endothelial cell growth by pericytes and
979 smooth muscle cells. *J Cell Biol* **105**, 1455-1462 (1987).

980 38 Hayashi, K. et al. Effects of hypoxia on endothelial/pericytic co-culture model of the blood-
981 brain barrier. *Regul Pept* **123**, 77-83, doi:10.1016/j.regpep.2004.05.023 (2004).

982 39 Hori, S., Ohtsuki, S., Hosoya, K., Nakashima, E. & Terasaki, T. A pericyte-derived
983 angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary
984 endothelial cells through Tie-2 activation in vitro. *J Neurochem* **89**, 503-513,
985 doi:10.1111/j.1471-4159.2004.02343.x (2004).

986 40 Janzer, R. C. & Raff, M. C. Astrocytes induce blood-brain barrier properties in endothelial cells.
987 *Nature* **325**, 253-257 (1987).

988 41 Kuchler-Bopp S., Delaunoy J.-P., Artault J.-C., Zaepfel, M. & Dietrich, J.-B. Astrocytes induce
989 several blood-brain barrier properties in non-neural endothelial cells. *Neuroreport* **10**, 1347-
990 1353 (1999).

991 42 Sobue, K. et al. Induction of blood-brain barrier properties in immortalized bovine brain
992 endothelial cells by astrocytic factors. *Neurosci. Res.* **35**, 155–164 (1999).

993 43 Nakagawa, S. et al. Pericytes from brain microvessels strengthen the barrier integrity in primary
994 cultures of rat brain endothelial cells. *Cell Mol Neurobiol* **27**, 687-694, doi:10.1007/s10571-
995 007-9195-4 (2007).

996 44 Nakagawa, S. et al. A new blood-brain barrier model using primary rat brain endothelial cells,
997 pericytes and astrocytes. *Neurochem. Int.* **54**, 253-263, doi:10.1016/j.neuint.2008.12.002
998 (2009).

999 45 Iwao, T. et al. Brain pericytes enhance MFSD2A expression and plasma membrane localization
1000 in brain endothelial cells through the PDGF-BB/PDGFR β Signaling Pathway. *Int J Mol Sci* **26**,
1001 5949, doi:10.3390/ijms26135949 (2025).

1002 46 Fu, J. et al. Astrocyte-derived TGF β 1 facilitates blood-brain barrier function via non-canonical
1003 hedgehog signaling in brain microvascular endothelial cells. *Brain Sci* **11**, 77,
1004 doi:10.3390/brainsci11010077 (2021).

1005 47 Igarashi, Y., Utsumi, H., Chiba, H., Yamada-Sasamori, Y., Tobioka, H., Kamimura, Y.,
1006 Furuuchi, K., Kokai, Y., Nakagawa, T., Mori, M., Sawada, N. Glial cell line-derived
1007 neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier.
1008 *Biochem Biophys Res Commun* **261**, 108–112 (1999).

1009 48 Simonneau, C. et al. Investigating receptor-mediated antibody transcytosis using blood-brain
1010 barrier organoid arrays. *Fluids Barriers CNS* **18**, 43, doi:10.1186/s12987-021-00276-x (2021).

1011 49 Bell, L. et al. Advanced tissue technologies of blood-brain barrier organoids as high throughput
1012 toxicity readouts in drug development. *Heliyon* **11**, e40813, doi:10.1016/j.heliyon.2024.e40813
1013 (2025).

1014 50 Bay, C. et al. Novel paracellular marker based on D-dipeptide structure for highly sensitive
1015 quantification with UPLC-MS/MS for in vitro and in vivo blood-brain barrier permeability
1016 analysis. *Fluids Barriers CNS* **23**, doi:10.1186/s12987-026-00806-5 (2026).

1017 51 Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods* **9**,
1018 676-682, doi:10.1038/nmeth.2019 (2012).

1019 52 Kmiecik, S. W. et al. Validation of a UPLC-MS/MS method for quantifying intracellular
1020 olaparib levels in resistant ovarian cancer cells. *Pharmaceuticals* **18**, 1870,
1021 doi:10.3390/ph18121870 (2025).

1022 53 Sigaud, R. et al. The first-in-class ERK inhibitor ulixertinib shows promising activity in
1023 mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models. *Neuro*
1024 *Oncol* **25**, 566-579, doi:10.1093/neuonc/noac183 (2023).

1025 54 Bergamino M, S. M., Uhl P, Bay C, Meid AD, Stuß N, Burhenne J, Czock D, Blank A, Haefeli
1026 WE. Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of
1027 ascending single oral doses of octreotide/LipOra peptide in healthy volunteers. Poster P077, 11th
1028 German Pharm-Tox Summit 2026, *Naunyn-Schmiedeberg's Arch Pharmacol* **399** (Suppl 1), 39,
1029 doi.org/10.1007/s00210-026-05123-0 (2026).

1030 55 Kumar, P., Saini, V., Gupta, D., Chawla, P. A. & Kumar, A. BBBper: A machine learning-based
1031 online tool for blood-brain barrier (BBB) permeability prediction. *CNS Neurol Disord Drug*
1032 *Targets* **25**, 130-138, doi:10.2174/0118715273328174241007060331 (2026).

1033 56 Shaker, B. et al. A machine learning-based quantitative model (LogBB_Pred) to predict the
1034 blood-brain barrier permeability (logBB value) of drug compounds. *Bioinformatics* **39**, btad577,
1035 doi:10.1093/bioinformatics/btad577 (2023).

1036 57 Martins, I. F., Teixeira, A. L., Pinheiro, L. & Falcao, A. O. A Bayesian approach to in silico
1037 blood-brain barrier penetration modeling. *J Chem Inf Model* **52**, 1686-1697,
1038 doi:10.1021/ci300124c (2012).

1039 58 Tian, H., Ketkar, R. & Tao, P. ADMETboost: a web server for accurate ADMET prediction. *J*
1040 *Mol Model* **28**, 408, doi:10.1007/s00894-022-05373-8 (2022).

1041 59 Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate
1042 pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci*
1043 *Rep* **7**, 42717, doi:10.1038/srep42717 (2017).

1044 60 Daina, A. & Zoete, V. A BOILED-Egg to predict gastrointestinal absorption and brain
1045 penetration of small molecules. *ChemMedChem* **11**, 1117-1121, doi:10.1002/cmdc.201600182
1046 (2016).

1047 61 Nzou, G. et al. Human cortex spheroid with a functional blood brain barrier for high-throughput
1048 neurotoxicity screening and disease modeling. *Sci Rep* **8**, 7413, doi:10.1038/s41598-018-25603-
1049 5 (2018).

1050 62 Dao, L. et al. Modeling blood-brain barrier formation and cerebral cavernous malformations in
1051 human PSC-derived organoids. *Cell Stem Cell* **31**, 818-833 e811,
1052 doi:10.1016/j.stem.2024.04.019 (2024).

1053 63 Campisi, M. et al. 3D self-organized microvascular model of the human blood-brain barrier with
1054 endothelial cells, pericytes and astrocytes. *Biomaterials* **180**, 117-129,
1055 doi:10.1016/j.biomaterials.2018.07.014 (2018).

1056 64 Katt, M. E. & Shusta, E. V. In vitro models of the blood-brain barrier: Building in physiological
1057 complexity. *Curr Opin Chem Eng* **30**, 42-52, doi:10.1016/j.coche.2020.07.002 (2020).

1058 65 Hajal, C. et al. Engineered human blood-brain barrier microfluidic model for vascular
1059 permeability analyses. *Nat Protoc* **17**, 95-128, doi:10.1038/s41596-021-00635-w (2022).

1060 66 Huang, E. T. C. et al. Predicting blood-brain barrier permeability of molecules with a large
1061 language model and machine learning. *Sci Rep* **14**, 15844, doi:10.1038/s41598-024-66897-y
1062 (2024).

1063 67 Alarcon-Martinez, L., Yemisci, M. & Dalkara, T. Pericyte morphology and function. *Histol*
1064 *Histopathol* **36**, 633-643, doi:10.14670/HH-18-314 (2021).

1065 68 Hartmann, D. A. et al. Pericyte structure and distribution in the cerebral cortex revealed by high-
1066 resolution imaging of transgenic mice. *Neurophotonics* **2**, 041402,
1067 doi:10.1117/1.NPh.2.4.041402 (2015).

1068 69 Muoio, V., Persson, P. B. & Sendeski, M. M. The neurovascular unit - concept review. *Acta*
1069 *Physiol* **210**, 790-798, doi:10.1111/apha.12250 (2014).

1070 70 Verkhatsky, A., Zorec, R. & Parpura, V. Stratification of astrocytes in healthy and diseased
1071 brain. *Brain Pathol* **27**, 629-644, doi:10.1111/bpa.12537 (2017).

1072 71 Wevers, N. R. et al. A perfused human blood-brain barrier on-a-chip for high-throughput
1073 assessment of barrier function and antibody transport. *Fluids Barriers CNS* **15**, 23,
1074 doi:10.1186/s12987-018-0108-3 (2018).

1075 72 Balzer, V. et al. Re-evaluation of the hCMEC/D3 based in vitro BBB model for ABC transporter
1076 studies. *Eur J Pharm Biopharm* **173**, 12-21, doi:10.1016/j.ejpb.2022.02.017 (2022).

1077 73 Weksler, B. B. et al. Blood-brain barrier-specific properties of a human adult brain endothelial
1078 cell line. *FASEB Journal* **19**, 1872-1874 (2005).

1079 74 Sasson, E. et al. Nano-scale architecture of blood-brain barrier tight-junctions. *Elife* **10**,
1080 doi:10.7554/eLife.63253 (2021).

1081 75 Tornavaca, O. et al. ZO-1 controls endothelial adherens junctions, cell-cell tension,
1082 angiogenesis, and barrier formation. *J Cell Biol* **208**, 821-838, doi:10.1083/jcb.201404140
1083 (2015).

1084 76 Biemans, E., Jakel, L., de Waal, R. M. W., Kuiperij, H. B. & Verbeek, M. M. Limitations of the
1085 hCMEC/D3 cell line as a model for Abeta clearance by the human blood-brain barrier. *J.*
1086 *Neurosci. Res.* **95**, 1513-1522, doi:10.1002/jnr.23964 (2017).

1087 77 Hinkel, S., Mattern, K., Dietzel, A., Reichl, S. & Muller-Goymann, C. C. Parametric
1088 investigation of static and dynamic cell culture conditions and their impact on hCMEC/D3
1089 barrier properties. *Int J Pharm* **566**, 434-444, doi:10.1016/j.ijpharm.2019.05.074 (2019).

1090 78 Paranjape, A. N., D'Aiuto, L., Zheng, W., Chen, X. & Villanueva, F. S. A multicellular brain
1091 spheroid model for studying the mechanisms and bioeffects of ultrasound-enhanced drug
1092 penetration beyond the blood-brain barrier. *Sci Rep* **14**, 1909, doi:10.1038/s41598-023-50203-
1093 3 (2024).

1094 79 Ebisawa, A. et al. Human blood-brain barrier spheroid models for the evaluation of drugs
1095 targeting brain vascular inflammation. *J. Pharmacol. Sci.* **162**, 40-49,
1096 doi:10.1016/j.jphs.2026.06.005 (2026).

1097 80 Mathew-Schmitt, S. et al. Generation of advanced blood-brain barrier spheroids using human-
1098 induced pluripotent stem cell-derived brain capillary endothelial-like cells. *Adv Biol* **9**,
1099 e2400442, doi:10.1002/adbi.202400442 (2025).

1100 81 Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a
1101 summary. *Neuro Oncol* **23**, 1231-1251, doi:10.1093/neuonc/noab106 (2021).

1102 82 Louis, D. N. et al. cIMPACT-NOW update 6: new entity and diagnostic principle
1103 recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and
1104 grading. *Brain Pathol* **30**, 844-856, doi:10.1111/bpa.12832 (2020).

1105 83 EMA; New medicine to treat paediatric low-grade glioma, 27.02.2026;
1106 [https://www.ema.europa.eu/en/news/new-medicine-treat-paediatric-low-grade-glioma; last
1107 06.06.2026].

1108 84 Venkataramani, V. et al. Glioblastoma hijacks neuronal mechanisms for brain invasion. *Cell*
1109 **185**, 2899-2917 e2831, doi:10.1016/j.cell.2022.06.054 (2022).

1110 85 Venkataramani, V. et al. Glutamatergic synaptic input to glioma cells drives brain tumour
1111 progression. *Nature* **573**, 532-538, doi:10.1038/s41586-019-1564-x (2019).

1112 86 Eschen, J. T. et al. SENIPERA Phase 0/1 randomized window-of-opportunity clinical trial of
1113 SENIcapoc and PERAmpanel mono- and combination therapy of newly diagnosed
1114 glioblastoma: a trial protocol. *BMC Cancer* **26**, 667, doi:10.1186/s12885-026-15784-y (2026).

1115 87 Hausmann, D. et al. Autonomous rhythmic activity in glioma networks drives brain tumour
1116 growth. *Nature* **613**, 179-186, doi:10.1038/s41586-022-05520-4 (2023).

1117 88 Liu, K. H., Yang, S. T., Lin, Y. K., Lin, J. W., Lee, Y. H., Wang, J. Y., Hu, C. J., Lin, E. Y.,
1118 Chen, S. M., Then, C. K., Shen, S. C. Fluoxetine, an antidepressant, suppresses glioblastoma by
1119 evoking AMPAR-mediated calcium-dependent apoptosis. *Oncotarget* **6**, 5088–5101 (2014).

1120 89 Grant, N. et al. Blood brain barrier permeability prediction with artificial intelligence and
1121 machine learning: a meta-review and future directions. *Discov. Artif. Intell.* **5**, 254,
1122 doi:10.1007/s44163-025-00494-4 (2025).

1123 90 Loryan, I. et al. Unbound brain-to-plasma partition coefficient, $K(p,uu,brain)$ -a game changing
1124 parameter for CNS drug discovery and development. *Pharm Res* **39**, 1321-1341,
1125 doi:10.1007/s11095-022-03246-6 (2022).

1126 91 Chowdhury, E. A. et al. Understanding the brain uptake and permeability of small molecules
1127 through the BBB: A technical overview. *J Cereb Blood Flow Metab* **41**, 1797-1820,
1128 doi:10.1177/0271678X20985946 (2021).

1129 92 Benzel, J. et al. Investigating the central nervous system disposition of actinomycin D:
1130 implementation and evaluation of cerebral microdialysis and brain tissue measurements
1131 supported by UPLC-MS/MS quantification. *Pharmaceutics* **13**, 1498,
1132 doi:10.3390/pharmaceutics13091498 (2021).

1133 93 Maurer, T. S., Debartolo, D. B., Tess, D. A. & Scott, D. O. Relationship between exposure and
1134 nonspecific binding of thirty-three central nervous system drugs in mice. *Drug Metab Dispos*
1135 **33**, 175-181, doi:10.1124/dmd.104.001222 (2005).

1136 94 Westerhout, J., Ploeger, B., Smeets, J., Danhof, M. & de Lange, E. C. Physiologically based
1137 pharmacokinetic modeling to investigate regional brain distribution kinetics in rats. *AAPS J* **14**,
1138 543-553, doi:10.1208/s12248-012-9366-1 (2012).

1139 95 Groseclose, M. R. et al. Assessment of brain penetration and tumor accumulation of niraparib
1140 and olaparib: insights from multimodal imaging in preclinical models. *Sci Rep* **15**, 33670,
1141 doi:10.1038/s41598-025-18255-9 (2025).

1142 96 Hanna, C. et al. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for
1143 recurrent glioblastoma: results of the phase I OPARATIC trial. *Neuro Oncol* **22**, 1840-1850,
1144 doi:10.1093/neuonc/noaa104 (2020).

1145 97 Majd, N. et al. Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Lower Grade
1146 Gliomas in Adults. Poster CTNI-46 [<https://biomed-valley.com/wp-content/uploads/2024/12/SNO2024ulixertinibposter110124.pdf>; last accessed 15.10.2026],
1147 Society of Neuro-Oncology 29th annual meeting and education day, Houston, TX, *Neuro Oncol*
1148 **26**, Issue Supplement_8, doi.org/10.1093/neuonc/noae165.0413 (2024).

1150 98 Eugene, A. R. Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a
1151 therapeutic role in COVID-19 at a minimum dose of 20 mg per day. *F1000Research* **10**, 477,
1152 doi:10.12688/f1000research.53275.3 (2021).

1153 99 Magalhaes, P., Alves, G., Fortuna, A., Llerena, A. & Falcao, A. Real-world clinical
1154 characterization of subjects with depression treated with antidepressant drugs focused on (non-
1155)genetic factors, pharmacokinetics, and clinical outcomes: GnG-PK/PD-AD study. *Exp Clin*
1156 *Psychopharmacol* **28**, 202-215, doi:10.1037/pha0000294 (2020).

1157 100 Gao, L. et al. A phase I, open-label, single-dose study to evaluate the effect of hepatic
1158 impairment on the pharmacokinetics and safety of futibatinib. *Clin Transl Sci* **16**, 1713-1724,
1159 doi:10.1111/cts.13585 (2023).

1160 101 Hong, D. S. et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label,
1161 phase I dose-escalation study. *Ann Oncol* **30**, 325-331, doi:10.1093/annonc/mdy539 (2019).

1162 102 Chen, J. et al. Pharmacokinetics of lorlatinib after single and multiple dosing in patients with
1163 anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer: Results from a global
1164 phase I/II Study. *Clin Pharmacokinet* **60**, 1313-1324, doi:10.1007/s40262-021-01015-z (2021).

1165 103 Novartis. Sandostatin® LAR® (2020); [[https://www.novartis.com/sg-
1166 en/sites/novartis_sg/files/SandostatinLAR-Apr2020.SIN-App180620.pdf](https://www.novartis.com/sg-en/sites/novartis_sg/files/SandostatinLAR-Apr2020.SIN-App180620.pdf); last accessed
1167 02.06.26].

1168 104 Baum, J. et al. Olaparib in an ovarian cancer patient with end-stage renal disease and
1169 hemodialysis. *Cancer Chemother Pharmacol* **91**, 325-330, doi:10.1007/s00280-023-04514-x
1170 (2023).

1171 105 Overbeek, J. K. et al. Pharmacokinetic boosting of olaparib: A randomised, cross-over study
1172 (PROACTIVE-study). *Eur J Cancer* **194**, 113346, doi:10.1016/j.ejca.2023.113346 (2023).

1173 106 Metro, G. et al. Repotrectinib's clinical benefit and its brain penetration in a patient with
1174 meningeal carcinomatosis from G2032R-mutated ROS-1 positive non-small cell lung cancer.
1175 *Oncol Ther* **12**, 163-171, doi:10.1007/s40487-023-00251-6 (2024).

1176 107 EMA. Assessment report Nexpovio (Selinexor). (2022).
1177 [[https://www.ema.europa.eu/en/documents/variation-report/nexpovio-h-c-005127-ii-0001-g-
1178 epar-assessment-report_en.pdf](https://www.ema.europa.eu/en/documents/variation-report/nexpovio-h-c-005127-ii-0001-g-epar-assessment-report_en.pdf); last accessed 02.06.2026].

1179 108 Sparidans, R. W., Li, W., Schinkel, A. H. & Beijnen, J. H. Bioanalytical assay for the novel
1180 TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid
1181 chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*
1182 **1122-1123**, 78-82, doi:10.1016/j.jchromb.2019.05.026 (2019).

1183 109 Ataga, K. I. et al. Improvements in haemolysis and indicators of erythrocyte survival do not
1184 correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III
1185 randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc
1186 (ICA-17043). *Br J Haematol* **153**, 92-104, doi:10.1111/j.1365-2141.2010.08520.x (2011).

1187 110 Pfizer Pharma GmbH; Fachinformation Torisel® 30 mg Konzentrat und Lösungsmittel zur
1188 Herstellung einer Infusionslösung. (2024). [[https://figi.pfizer.de/sites/default/files/FI-
1189 10635.pdf](https://figi.pfizer.de/sites/default/files/FI-10635.pdf); last accessed 02.06.26].

1190 111 Mendzelevski, B. et al. Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval
1191 in patients with advanced solid tumor malignancies. *Cancer Chemother Pharmacol* **81**, 1129-
1192 1141, doi:10.1007/s00280-018-3564-1 (2018).

1193 112 Johnson, R. D., Lewis, R. J. & Angier, M. K. The distribution of fluoxetine in human fluids and
1194 tissues. *Journal of Analytical Toxicology* **31**, 409-414 (2007).

1195 113 Bolo N. et al. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and
1196 fluoxetine by fluorine magnetic resonance spectroscopy. *Neuropsychopharmacology* **23**, 428-
1197 438 (2000).

1198 114 Karson C.N. et al. Human brain fluoxetine concentrations. *J Neuropsychiatry Clin Neurosci* **5**,
1199 322-329 (1993).

1200 115 Renshaw P.F., Guimaraes A.R., Fava M, Rosenbaum JF, Pearlman JD, Flood JG, Puopolo PR,
1201 Clancy K, Gonzalez RG. Accumulation of fluoxetine and norfluoxetine in human brain during
1202 therapeutic administration. *Am J Psychiatry* **149**, 1592-1594 (1992).

1203 116 Jermakowicz, A. M. et al. RAPID resistance to BET inhibitors is mediated by FGFR1 in
1204 glioblastoma. *Sci Rep* **14**, 9284, doi:10.1038/s41598-024-60031-8 (2024).

1205 117 Wang, X. et al. Advances on fluid shear stress regulating blood-brain barrier. *Microvasc Res*
1206 **128**, 103930, doi:10.1016/j.mvr.2019.103930 (2020).

1207 118 Sun, S., Pithavala, Y. K., Martini, J. F. & Chen, J. Evaluation of lorlatinib cerebrospinal fluid
1208 concentrations in relation to target concentrations for anaplastic lymphoma kinase (ALK)
1209 inhibition. *J Clin Pharmacol* **62**, 1170-1176, doi:10.1002/jcph.2056 (2022).

1210 119 Shaw, A. T. et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement:
1211 an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol* **18**,
1212 1590-1599, doi:10.1016/S1470-2045(17)30680-0 (2017).

1213 120 Chen, W. et al. Pharmacokinetic study and tissue distribution of lorlatinib in mouse serum and
1214 tissue samples by liquid chromatography-mass spectrometry. *J Anal Methods Chem* 2019,
1215 7574369, doi:10.1155/2019/7574369 (2019).

1216 121 Chen, W. et al. A comprehensive analysis of metabolomics and transcriptomics reveals novel
1217 biomarkers and mechanistic insights on lorlatinib crosses the blood-brain barrier. *Front*
1218 *Pharmacol* **12**, 722627, doi:10.3389/fphar.2021.722627 (2021).

1219 122 Li, W. et al. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome
1220 P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. *Int J*
1221 *Cancer* **143**, 2029-2038, doi:10.1002/ijc.31582 (2018).

1222 123 Csaba, Z. et al. A simple novel approach for detecting blood-brain barrier permeability using
1223 GPCR internalization. *Neuropathol Appl Neurobiol* **47**, 297-315, doi:10.1111/nan.12665
1224 (2021).

1225 124 Lewis, R. J., Kemp, P. M. & Johnson, R. D. Distribution of paroxetine in postmortem fluids and
1226 tissues. FAA, Office of Aerospace Medicine (2015).

1227 125 Silva, S. et al. Intranasal delivery of paroxetine: A preclinical study on pharmacokinetics,
1228 depressive-like behaviour, and neurochemical sex differences. *Biochem Pharmacol* **223**,
1229 116184, doi:10.1016/j.bcp.2024.116184 (2024).

1230 126 Silva, S. et al. Encapsulated escitalopram and paroxetine intranasal co-administration: In
1231 vitro/in vivo Evaluation. *Front Pharmacol* **12**, 751321, doi:10.3389/fphar.2021.751321 (2021).

1232 127 Li, W. et al. ABCB1 and ABCG2 restrict brain and testis accumulation and, alongside CYP3A,
1233 limit oral availability of the novel TRK inhibitor selitrectinib. *Mol Cancer Ther* **20**, 1173-1182,
1234 doi:10.1158/1535-7163.MCT-20-0705 (2021).

1235 128 Roa, P. et al. Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity
1236 against NTRK fusion-positive tumours with on-target resistance to first-generation agents. *Br J*
1237 *Cancer* **131**, 601-610, doi:10.1038/s41416-024-02760-1 (2024).

1238 129 Green, A. L. et al. Preclinical antitumor efficacy of selective exportin 1 inhibitors in
1239 glioblastoma. *Neuro Oncol* **17**, 697-707, doi:10.1093/neuonc/nou303 (2015).

1240 130 Jin, L. W. et al. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease. *Ann Clin*
1241 *Transl Neurol* **6**, 723-738, doi:10.1002/acn3.754 (2019).

1242 131 Staal, R. G. W. et al. Inhibition of the potassium channel K(Ca)3.1 by senicapoc reverses tactile
1243 allodynia in rats with peripheral nerve injury. *Eur J Pharmacol* **795**, 1-7,
1244 doi:10.1016/j.ejphar.2016.11.031 (2017).

1245 132 FDA. Center for drug evaluation and research; Clinical pharmacology review Torisel. (2006).
1246 [https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022088s000_ClinPharmR.pdf; last
1247 accessed 07.06.2026].

1248 133 Kuhn, J. G. et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in
1249 patients with recurrent malignant glioma. *Clin Cancer Res* **13**, 7401-7406, doi:10.1158/1078-
1250 0432.CCR-07-0781 (2007).

1251 134 Korfel, A. et al. Phase II trial of temsirolimus for relapsed/refractory primary CNS lymphoma.
1252 *J Clin Oncol* **34**, 1757-1763, doi:10.1200/JCO.2015.64.9897 (2016).

1253 135 Weiss, J. et al. Inhibition of P-glycoprotein by newer antidepressants. *J Pharmacol Exp Ther*
1254 **305**, 197-204, doi:10.1124/jpet.102.046532 (2003).

1255 136 Gutmann H, M. D., Droulle A, Drewe J, Fahr A, Fricker G. P-glycoprotein- and mrp2-mediated
1256 octreotide transport in renal proximal tubule. *Br J Pharmacol*. **129**, 251-256 (2000).

1257 137 Wen, P. Y. et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent
1258 malignant gliomas: North American Brain Tumor Consortium trial 04-02. *Neuro Oncol* **16**, 567-
1259 578, doi:10.1093/neuonc/not247 (2014).

1260 138 Balakrishna, V. A. et al. Preclinical assessment of ulixertinib, a novel ERK1/2 inhibitor.
1261 *ADMET and DMPK* **5**, 212-223, doi:10.5599/admet.5.4.437 (2017).

1262 139 Ji, N. et al. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated
1263 chemotherapeutic drug resistance. *Biochem Pharmacol* **158**, 274-285,
1264 doi:10.1016/j.bcp.2018.10.028 (2018).

1265 140 Sullivan, R. J. et al. First-in-Class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with
1266 MAPK mutant advanced solid tumors: Results of a phase I dose-escalation and expansion Study.
1267 *Cancer Discov* **8**, 184-195, doi:10.1158/2159-8290.CD-17-1119 (2018).

1268 141 Vo, K. T. et al. Phase II study of ulixertinib in children and young adults with tumors harboring
1269 activating mitogen-activated protein kinase pathway alterations: APEC1621J of the national
1270 cancer institute-children's oncology group pediatric MATCH trial. *JCO Precis Oncol* **8**,
1271 e2400103, doi:10.1200/PO.24.00103 (2024).

1272 142 Long, A. et al. A phase I drug-drug interaction study to assess the effect of futibatinib on P-gp
1273 and BCRP substrates and of P-gp inhibition on the pharmacokinetics of futibatinib. *Clin Transl*
1274 *Sci* **17**, e70012, doi:10.1111/cts.70012 (2024).

1275 143 Meric-Bernstam, F. et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with
1276 advanced solid tumors harboring FGF/FGFR aberrations: A phase I dose-expansion study.
1277 *Cancer Discov* **12**, 402-415, doi:10.1158/2159-8290.CD-21-0697 (2022).

1278 144 Wang, Y. et al. OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK
1279 inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. *Br J*
1280 *Pharmacol* **177**, 3060-3074, doi:10.1111/bph.15034 (2020).

1281 145 Laetsch, T. W. et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions:
1282 phase 1 results from a multicentre, open-label, phase 1/2 study. *Lancet Oncol* **19**, 705-714,
1283 doi:10.1016/S1470-2045(18)30119-0 (2018).

1284 146 Drilon A. et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase
1285 fusion–positive lung cancers. *Precis Oncol* **6**, e2100418, doi:10.1200/PO.21 (2022).

1286 147 Solomon, B. J. et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-
1287 small cell lung cancer: 5-Year outcomes from the phase III CROWN study. *J Clin Oncol* **42**,
1288 3400-3409, doi:10.1200/JCO.24.00581 (2024).

1289 148 Li, W., Sparidans, R. W., Lebre, M. C., Beijnen, J. H. & Schinkel, A. H. ABCB1 and ABCG2
1290 control brain accumulation and intestinal disposition of the novel ROS1/TRK/ALK inhibitor
1291 repotrectinib, while OATP1A/1B, ABCG2, and CYP3A limit its oral availability.
1292 *Pharmaceutics* **13**, 1761, doi:10.3390/pharmaceutics13111761 (2021).

1293 149 Wachter, F. et al. Molecular characterization of inflammatory tumors facilitates initiation of
1294 effective therapy. *Pediatrics* **148**, e2021050990, doi:10.1542/peds.2021-050990 (2021).

1295 150 Drilon, A. et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. *N Engl J*
1296 *Med* **390**, 118-131, doi:10.1056/NEJMoa2302299 (2024).

1297

1298 **Table 1:** Used drug concentrations and the reported *in vivo* steady-state or $c_{\max}$ -concentrations

drug	Used concentration [ng/mL] [μM]	Steady-state/ $c_{\max}$ concentration [ng/mL]
Fluoxetine	150 50 15 0.48 0.16 0.048	Human steady state 25.1; 215 (~50 % NFLU) 98,99
Futibatinib	300 100 30 0.72 0.24 0.072	Human $c_{\max}$ ~ 100 100
Larotrectinib	1800 600 180 4.20 1.40 0.420	Human $c_{\max}$ in steady state 914 101
Lorlatinib	1500 500 150 3.69 1.23 0.369	Human $c_{\max}$ in steady state 576.5 102
Octreotide	100 10 1 0.098 0.0098 0.00098	Human steady state 1.56-2.97 103
Olaparib	50000 15000 5000 115 34.5 11.5	Human steady state $c_{\max}$ 6370 $c_{\max}$ 4740 104,105
Paroxetine	300 100 30 0.91 0.3 0.091	Human steady state 50.1 99
Repotrectinib	3000 1000 300 8.44 2.81 0.844	Human steady state 1317 106
Selinexor	300 100 30 0.677 0.226 0.0677	Human $c_{\max}$ 693 107
Selitrectinib	15000 5000 1500 39.47 13.16 3.947	Mice $c_{\max}$ 6623 108
Senicapoc	2000 666.67 200 6.19 2.06 0.619	Human steady state 137 109
Temsirolimus	2000 666.67 200 1.94 0.46 0.194	Human $c_{\max}$ ~2500 110
Ulixertinib	3000 1000 300 6.9 2.3 0.69	Human $c_{\max}$ and steady state 2031 111

1299 NFLU = norfluoxetine; $c_{\max}$ = maximum concentration.

1300 **Table 2:** Sample preparation for drug quantification

Drug	Calibration range [ng/mL]	System	Sample preparation
Fluoxetine	0.3 - 300	TQ-S1	Liquid-liquid extraction with 50 µL borat buffer (pH 9) and 700 µL TBME. After 10 min overhead shaking, 150 µL of supernatant was transferred and evaporated. Samples were redissolved in 200 µL H ₂ O/ACN (95/5, v/v) + 0.1% FA.
Octreotide	0.03 - 10	TQ-S2	Protein precipitation with 150 µl ACN + 0.1% FA, evaporated, redissolved in 100 µL H ₂ O + 0.1% FA.
Olaparib	0.1 - 300	TQ-XS	Protein precipitation with 150 µl ACN + 0.1% FA, evaporated, redissolved in 100 µL H ₂ O/ACN (95/5, v/v) + 0.1% FA.
Paroxetine	1 - 1000	TQ-S2	Protein precipitation with 150 µl ACN + 0.1% FA and 200 µL H ₂ O + 0.1% FA added.
Selinexor	0.1 - 3	TQ-S1	Protein precipitation with 100 µl ACN + 0.1% FA, evaporated, redissolved in 100 µL H ₂ O/ACN (95/5, v/v) + 0.1 % FA.
Senicapoc	1 - 3000	TQ-S1	Protein precipitation with 150 µl ACN + 0.1% FA, evaporated, redissolved in 100 µL H ₂ O/ACN (95/5, v/v) + 0.1 % FA.
Temsirolimus	0.1 - 1000	TQ-S1	Protein precipitation with 150 µl ACN + 0.1% FA and 200 µL H ₂ O + 0.1% FA added.
Ulixertinib	0.1 - 100	TQ-S2	Protein precipitation with 150 µl ACN + 0.1% FA and 200 µL H ₂ O + 0.1% FA added.
Multimethod for tyrosine kinase inhibitors (TKI)			
Futibatinib	0.03 - 30	TQ-S1	Protein precipitation with 100 µl ACN + 0.1% FA, evaporated and redissolved in 100 µL H ₂ O/ACN (95/5, v/v) + 0.1% FA.
Larotrectinib	0.01 - 10		
Lorlatinib	0.03 - 30		
Repotrectinib	0.01 - 10		
Selitrectinib	0.01 - 10		

1301

1302 **Table 3:** Reported *in vivo* brain-to-plasma ratio of the evaluated drugs

drug mean $\pm$ SD	Brain-to-plasma ratio				
Fluoxetine 15.4 $\pm$ 4.39	15 $\pm$ 3 human ^m , B/P _{ss} 112	10 $\pm$ 6 human ^m , B/P _{ss} 113	21.2 $\pm$ 16.2 human ^m , B/P _{ss} ^c 114	2.6 $\pm$ 1 human ^m , B/P _{ss} ^c 115	
Futibatinib 0.17 $\pm$ 0.05	~0.17 $\pm$ 0.05 mice ^{BT} , B/P _{2h} 116				
Larotrectinib 0.06 $\pm$ 0.012	0.036 $\pm$ 0.01 mice, B/P _{4h}	0.05 $\pm$ 0.02 mice, B/P _{1h}	0.09 $\pm$ 0.03 mice, B/P _{8h}		117
Lorlatinib 0.63 $\pm$ 0.084	0.734 $\pm$ 0.124 human ^{z.T. BM} , CSF/P _{uu, ss} ^c 102,118,119		0.7 $\pm$ 0.2 mice, B/P _{AUC} 120,121	0.46 $\pm$ 0.06 mice, B/P _{8h} 122	
Octreotid 0	0 mice 123				
Olaparib 0.03 $\pm$ 0.008	0.026 macaques, K _{p,uu,brain} 95	0.041 macaques, K _{p, brain}	0.036 mice ^{BM} , K _{p, brain}	0.022 mice ^{BM} , K _{p,uu,brain} 96	0 rat
Paroxetine 0.97 $\pm$ 1.59	4.27 $\pm$ 2.64 human, B/P _{ss} 124	0.35 mice, K _{p, brain}	0.22 mice, K _{p,uu,brain} 125	0.38 mice, K _{p,brain}	0.25 mice, K _{p,uu,brain} 126
Repotrectinib 0.15 $\pm$ 0.06	0.246 Human ^{BM} , CSF/P _{uu, ss} ^c 106	0.15 $\pm$ 0.03 mice, B/P _{4h} 127	0.103 $\pm$ 0.011 B/P _{0.5h} ^c 128	0.091 $\pm$ 0.023 rat B/P _{2h} ^c	
Selinexor 0.68 $\pm$ 0.084	0.72 rat (individuals), B/P _{2h}	0.82 macaques (individuals), B/P _{2h}	0.62 macaques (individuals), B/P _{2h}	0.58 macaques (individuals), B/P _{2h}	0.65 macaques (individuals), B/P _{2h} 129
Selitrectinib 0.04 $\pm$ 0.014	0.021 $\pm$ 0.004 mice, B/P _{4h} 108	0.058 $\pm$ 0.042 B/P _{0.5h} ^c 128	0.041 $\pm$ 0.01 rat B/P _{2h} ^c		
Senicapoc 4.74 $\pm$ 2.26	~5 5 $\times$ FAD mice B/P _{n.a.} 130	7.32 $\pm$ 4.84 B/P _{1h}	7.07 $\pm$ 3.35 rat B/P _{4h} 131	2.2 $\pm$ 0.4 rat B/P _{uu, 1h}	2.1 $\pm$ 0.4 rat B/P _{uu, 4h}
Temsirolimus 0.72 $\pm$ 0.45	1.43 $\pm$ 0.90 Human ^{BT} , tumor/ blood _{ss} 133	0.0023 $\pm$ 0.0082 Human ^{BT} , CSF/P _{uu} ^c calculated with protein binding ¹³² 134			
Ulixertinib 0.67 $\pm$ 0.66	0.0176 mice ^{PDX} , B/P _{AUC} 53	1.33 $\pm$ 0.42 Human ^{BT} , CSF/P _{uu,ss} 97			

1303 ^c = calculated from reported data; ^m = with metabolite; ^{BM} = with brain metastasis; ^{BT} = with brain tumor; ^{PDX} =
1304 BT40 Xenograft PDX; B/P = brain-to-plasma ratio; B/P_{uu} = unbound brain-to-plasma ratio; B/P_{AUC} = AUC-brain
1305 to AUC-plasma ~ B/P_{ss} = brain-to-plasma ratio in steady state ~ K_{p,brain} = brain-to-plasma partition coefficient;
1306 B/P_{uu,ss} = unbound brain-to-plasma ratio in steady state ~ K_{p,uu,brain} = unbound brain-to-plasma partition coefficient;
1307 CSF/P_{uu} = CSF concentration-to-unbound plasma concentration; AUC = area under the curve.

1308 **Table 4:** Selected drugs and BBB relevant characteristics

drug	Mode of action	Efflux substrate	clogP MW	Relevance to brain tumor therapy
Fluoxetine	SSRI	P-gp ¹³⁵	4.57 309.3	Xenograft ⁸⁸
Octreotide	Somatostatin analog	P-gp and mrp2 ¹³⁶	2.51 1019	Negative control
Olaparib	PARP inhibitor	P-gp ⁹⁶	1.24 434.5	NCT01390571 ⁹⁶
Paroxetine	SSRI	P-gp ¹³⁵	4.23 329.4	Positive control
Selinexor	Exportin 1 inhibitor	-	2.68 443.3	NCT04421378
Senicapoc	K _{CA} 3.1 blocker	-	3.53 323.3	SENIPERA, EU-CT: 2025-522605-37-00 ⁸⁶
Temsirolimus	mTOR inhibitor	P-gp ¹¹⁰	7.46 1030	¹³⁷ NCT05773326
Ulixertinib	ERK1/2; MAPK mutations inhibitor	likely P-gp and BCRP ^{138,139}	4.34 433.3	NCT01781429 ¹⁴⁰ NCT03698994 ¹⁴¹ NCT05804227 ⁹⁷
TKI				
Futibatinib	FGFR inhibitor	P-gp ¹⁴²	1.96 418.5	¹⁴³
Larotrectinib	NTRK inhibitor	P-gp and BCRP ¹⁴⁴	2.00 428.4	NCT02637687 ¹⁴⁵ NCT02576431 ¹⁴⁶
Lorlatinib	ALK inhibitor	P-gp ¹²²	1.87 406.4	¹⁴⁷ NCT06333899
Repotrectinib	ALK-, ROS1-, and NTRK inhibitor	P-gp and BCRP ¹⁴⁸	2.96 355.4	NCT04094610 ¹⁴⁹ NCT03093116 ¹⁵⁰
Selitrectinib	NTRK inhibitor	P-gp and BCRP ¹²⁷	1.86 380.4	NCT03215511

1309 ALK: anaplastic lymphoma kinase; clogP: calculated logP with ChemDraw; ERK1/2: extracellular signal
1310 regulated kinase; FGFR: fibroblast growth factor receptor; K_{CA}3.1: calcium activated potassium channel; MAPK:
1311 mitogen-activated protein kinase; MW: molecular weight; mTOR: mechanistic target of rapamycin; NTRK:
1312 neurotrophic tyrosine receptor kinase; PARP: poly(ADP-ribose)-polymerase; ROS1: proto-oncogene 1; SSRI:
1313 selective serotonin reuptake inhibitor.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaryinformationlegends.docx](#)
- [BayOrganoidSupplementspreprint.docx](#)
- [ExtendedData1Reproduciblecodeforregression.pdf](#)
- [ExtendedData2RegressionData.csv](#)